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ABSTRACT 
 
 
 
 
 
Background: The miR-17∼92 cluster was among the first cluster of miRNAs to be linked to cancer. It is 
directly activated by the members of the MYC family of transcription factors and acts as a bona fide oncogene 
in several types of cancer, including lymphomas. miR-17∼92 is essential for mammalian development. Knock-
out mice die in utero or at birth with cardiovascular defects and impaired B-cell maturation. 
Aims:  Although miR-17∼92 is important for tumorigenesis and development both the molecular mechanisms 
and the prominent miRNAs acting in different contexts are still unknown. The main aim of our study was to 
identify the role played by different members of the miR-17∼92 cluster in B-cell lymphomas and vascular 
development. 
Materials and Methods: A mouse model of B-cell lymphomas and a conditional miR-17~92 KO mouse strain 
were employed to investigate the role of miR-17~92 in Myc-induced cancers. A GFP-based in vitro assay 
allowed us to rapidly verify the oncogenic potential of each miRNA family and to determine how mutations in 
the seed/non seed sequence affect miRNA function. Gene-expression profiling, computational prediction and an 
shRNA-mediated validation screening were used to identify miR-19 targets. miR-17∼92 involvement in 
vascular development was studied by means of Real time, western blot, ELISA and the CD-31 (PECAM) 
vascular staining. 
Results and Conclusions : Our results suggest that the expression of two members of the cluster, miR-19a and 
miR-19b, is necessary and largely sufficient to recapitulate the oncogenic potential of the full miR-17∼92 
cluster in Myc-driven B cell lymphomas. A systematic mutational analysis of miR-19b showed that single point 
mutation in the seed sequence impaired miR-19b anti-apoptotic activity. Finally, a chimeric miRNA (miR-19b 
seed/miR-20 non-seed) acted as effectively as miR-19b, suggesting that the specific sequence of non-seed 
region of miR-19 provides little additional substrate specificity. We identified the tumor suppressor PTEN as 
the critical miR-19b target and the principal mediator of its pro-survival activity. We also showed that miR-
17~92–null embryos have upregulation of VEGF, although it is unclear at this time whether miR-17~92 
suppresses VEGF expression directly or indirectly. 
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Introduction 
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miRNAs: functions and mechanism of action 
 
 
MicroRNAs (miRNAs) are a group of non-coding regulatory RNAs, 20-22 nucleotides in length, which have 
been shown to regulate several cellular processes such as proliferation, differentiation, apoptosis, cell 
metabolism and angiogenesis 1.  
MiRNAs are transcribed by the RNA Pol-II as pri-miRNAs and then processed into mature miRNAs by the 
sequential action of Drosha and Dicer ribonucleases 1 (Fig.1). Upon maturation, miRNAs are incorporated into 
the RNA-induced silencing complex (RISC). The key components of the RISC are the Argonaute (Ago) 
proteins. All Argonaute proteins share two main, highly conserved, structural features: the PAZ domain and the 
PIWI domain. The PAZ domain binds dsRNA while the PIWI domain has extensive homology to the RNAse H 
catalytic domain 2. In humans, only Ago2 (slicer) has endonucleolitic activity 3. 
miRNAs are able to coordinate the expression of entire sets of genes, thus finely tuning the mammalian 
transcriptome 1. MiRNAs can regulate gene expression by recognizing specific binding sites in the 3′ 
untranslated region (UTR) of target mRNA molecules mainly through their seed sequence (nt.2-8). Additional 
complementary regions are often found in the non-seed sequence (nt.9-22) 1. MiRNAs binding leads the 
degradation of the target mRNAs, to the inhibition of their translation, or both 1, 4. In animals, it has been 
recently proposed that downregulation of target genes mostly occurs through mRNA destabilization, with only a 
very modest effect on translational efficiency 5. 
To date over 1000 of miRNAs have been identified in humans. Interestingly, about 30% of miRNAs in both 
humans and mouse are organized in cluster 6-8. They are transcribed as a single polycistronic unit that is rapidly 
processed in order to obtain the single mature miRNAs. Evolutionary, this organization facilitates functional 
overlap and cooperativity among miRNAs. This would allow several miRNAs to coordinately regulate multiple 
nodes belonging to the same pathway or different pathways in a timely fashion 7, although this hypothesis has 
not been formally tested yet.  
In the last few years miRNAs have been shown to have a great impact in both normal cellular processes and 
cancer. They are highly conserved across vertebrates and have a fundamental role in controlling developmental 
pathways. Genes controlling developmental processes such as cell proliferation, cell death and differentiation 
are commonly associated with cancer, and many microRNAs are implicated in tumour development and 
progression 9. In fact, a significant number of miRNAs is located in tumour susceptibility loci in mice 10. 
miRNA ‘‘signatures’’ of human cancer have been found of great help for tumor classification and clinical 
outcome predictions 11, 12. 
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Fig. 1 miRNAs processing mechanism. miRNAs are transcribed in the nucleus as pri-miRNAs and 
subsequently processed by Drosha into pre-miRNAs. The pre-miRNA is exported to the cytoplasm and 
cleaved by dicer to produce the mature miRNA. Upon assembly into the RISC complex miRNAs are able to 
act on their targets through degradation of the messenger RNA, repression of translation or both (from Rana 
et al., 2007).  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miR-17∼92: The prototype of clustered miRNAs  
   
miR-17∼92 is a polycistronic miRNA cluster that encodes for 6 different miRNAs. It was first identified in 2004 
as part of a frequent amplified region in diffuse large B cell lymphomas (13q31-q32) 13.  Based on their seed 
sequence, the miRNAs belonging to the cluster can be grouped into 4 different families: miR-17, miR-18, miR-
19 and miR-92 (Fig.2). Each of these miRNAs can potentially regulate hundreds of target mRNAs. Moreover, 
coordinate expression of multiple miRNAs from the same locus allows them to cooperate in regulating several 
biological processes 14. miR-17∼92 known functions include regulation of cell cycle, proliferation, apoptosis 
and angiogenesis, and several targets have been identified to date including the tumor suppressor PTEN 15-17, the 
antiapoptotic protein Bim 18-21, and well-known cell cycle regulators such as p21 and E2F120, 22-25. 
Moreover two paralog clusters, miR-106b∼25 and miR-106a∼363, have been identified on human chromosomes 
7 and X respectively (Fig.2). The three clusters originated from a series of duplication and deletion events 
occurred during early vertebrate evolution 26. The sequence of each miRNA component, as well as the spatial 
organization of these miRNAs within the mir-17~92 family, is highly conserved across species and among all 
three paralogs 26. Because of their high homology they are likely to have overlapping functions and regulate a 
similar set of genes. In fact, members of the miR106b~25 cluster regulate cell cycle and promote proliferation 
by targeting E2F1 and p21/CDKN1A 20, 23, 27. Unlike the miR-17∼92 and miR-106b∼25 clusters, which are both 
abundantly expressed across many tissues and cell types, mir-106a∼363 cluster is expressed at very low or often 
undetectable level in both normal or cancer cells and tissue 18, 24. Two recent reports have underlined the 
oncogenic potential of the miR-106a∼363 cluster by showing that its promoter region is a frequent site of 
retroviral integration site 28, 29. To date it remains unclear whether expression of this miRNA cluster is restricted 
to a specific cell type or it simply represents a non-functional pseudogene 30.  
Fig.2 The miR-17 family of miRNA clusters. Spatial organization and seed families. (adapted from Ventura 
et al., 2008).  
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miRNAs and development 
 
 
The most striking evidence that miRNAs are absolutely required during mammalian development comes from 
the observation that the miRNA-processing factors Dicer, Drosha, Dgcr-8 and Ago-2 are essential for mouse 
viability 31. Knock out mice individually lacking one of these factors die at early stages with multiple 
developmental defects 32-35.  
More recently deletion of either single miRNAs or entire cluster have been performed to elucidate their role 
during development 31. miR-155 was among the first miRNAs to be deleted in vivo 36, 37. It was shown to have a 
prominent role in the mammalian immune system. Genetic ablation of this miRNA determines impaired B and 
T-cell response possibly due to deregulation of cytokine production 36, 37 and AID 38, 39.  
The embryonic lethality of Dicer knockout mice was partially attributed to defective angiogenesis 32. Several 
miRNAs are indeed able to regulate vascular development 40. miR-126 was the first vascular miRNA to be 
knocked out in mice. Loss-of-function studies in mice and zebrafish revealed an important function of miR-126 
in governing vascular integrity and angiogenesis 41, 42. Targeted deletion of miR-126 was also associated with 
partial embryonic lethality and defective response of endothelial cells to angiogenic factors 41, 42. 
 
 
miR-17∼92 role in development 
 
miR-17∼92 is essential for mammalian development. The miR-17∼92 knockout embryos die perinatally and are 
characterized by small size, defective ventricular septation in the heart, and hypoplastic lungs 18 (Fig. 3A, B, C). 
B-cell development is also strongly impaired in the absence of the cluster at the pro-B to pre-B transition stage 
18 (Fig. 3D). Surprisingly, deletion of the miR-106b∼25 and miR106a~363 paralogs, either alone or in 
combination, has no effects on mouse viability while compound mutants mice (miR-17∼92Δ/Δ; miR-106b∼25Δ/Δ) 
and miR-17∼92Δ/Δ; miR-106b∼25Δ/Δ; miR-106a∼363Δ/y) die at earlier stages (∼E13.5-14.5) with increased 
apoptosis, extensive hemorrhages and edemas throughout the body 18(Fig. 3E). Interestingly, in 2000 Miquerol 
et al. described a similar phenotype linking cardiovascular defects and increased vascular permeability to 
elevated levels of the angiogenic factor VEGF-A 43.  VEGF signaling is essential during cardiovascular 
development; therefore its levels are tightly regulated from embryo development to adult life 44. The importance 
of this gene is underlined by the finding that deletion of even a single VEGF allele causes embryonic lethality at 
early stages due to impaired angiogenesis 45, 46. Deletion of the VEGF receptor flk-1, also leads to early 
embryonic lethality due to defective blood vessels formation 47. Moreover VEGF is the most prominent 
angiogenic factor promoting tumor progression and a recognized therapeutic target 48. Indeed, a link between 
the miR-17∼92 family of microRNAs and VEGF has been recently established 49-51. Members of the miR-17/20 
family were shown to directly target VEGF and its major activator under hypoxia, Hif-1α, in tumor cells, thus 
finely tuning cell adaptation to low oxygen concentration 49-51.  
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miR-17∼92 
Fig. 3 miR-17∼92 pleiotropic roles in development. (A) Wild Type and Knock Out embryos at various 
developmental stages. (B) Hematoxylin-eosin staining of transversal sections of Wild Type and miR-17∼92 
Δneo/Δneo hearts at E18.5. The asterisk indicates the ventricular septal defect. (C) Hypoplastic lungs in miR-
17∼92 Δneo/Δneo embryos. (D) Flow cytometry plots of E18.5 Fetal liver cells showing a dramatic reduction in 
the number of pre-B cells in The miR-17∼92Δneo/Δneo  embryos. (E) Macroscopic appearance of double (miR-
17∼92Δ/Δ; miR-106b∼25Δ/Δ) and triple (miR-17∼92Δ/Δ; miR-106b∼25Δ/Δ; miR-106a∼363Δ/y) Knock Out 
embryos at E14.5. Notice the hemorrhagic and edematous area in the body. (Adapted from Ventura et al., 
2008) 
A 
B 
C 
D 
E 
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miRNAs and cancer 
 
miRNAs  have been classified as oncogene or tumor suppressor according to their ability to influence cancer-
related pathways 52 (Tab. 1). The first miRNAs implicated in cancer were miR-15a and miR-16-1, which are 
often deleted or downregulated in B-cell chronic lymphocytic leukemia 53. They were both classified as tumor 
suppressor miRNAs, giving their ability to target the antiapoptotic protein Bcl-2 54. More recently their tumor 
suppressor activity was confirmed in vivo 55. 
Among the miRNAs that have been identified as oncogenes, miR-155 overexpression alone in the B-cell 
compartment was shown to be sufficient to determine acute lymphoblastic leukemia and high-grade lymphoma 
in vivo 56. Noteworthy is also miR-21, an oncogenic miRNA frequently overexpressed in a variety of human 
cancers 57. By using loss and gain of function in a mouse model Medina et al. showed that miR-21 
overexpression alone promotes lymphoma onset. Moreover shutting down miR-21 expression leads to a 
complete tumor regression partly due to increased apoptosis, a mechanism known as “onco-miR addiction” 58. 
 
miR-17∼92 and cancer 
 
miR-17∼92, also known as oncomiR-1 59, is among the most potent oncogenic miRNAs. It was originally 
identified as a potential oncogene due to its genomic amplification and elevated expression in multiple 
hematopoietic malignancies, including diffuse large B-cell lymphomas, mantle cell lymphomas, and Burkitt’s 
lymphomas 13, 59-62. Over-expression of miR-17∼92 has been observed in multiple tumor types 63 including 
gastric 20, lung and thyroid cancer 64-66. The miR-17∼92 oncogenic role is supported by evidences of its 
involvement in multiple key biological processes such as cell proliferation, differentiation, apoptosis (reviewed 
in Mendell, 2008) 
In 2005 O’Donnell et al. showed that the transcription of miR-17∼92 is directly activated by the c-Myc 
oncogene 24. This finding was further confirmed by several reports that have shown a synergistic cooperation 
between c-Myc and miR-17∼92 in malignant lymphoma development 59, 60. Other studies additionally 
demonstrated that the c-Myc homologue N-Myc is able to activate the expression of the cluster in 
neuroblastoma e medulloblastoma 67, 68. In 2008 Xiao et al. showed that a moderate miR-17∼92 overexpression 
(2-3 fold) in vivo determines a lymphoproliferative disorder, autoimmunity, enhances B-cell proliferation and 
reduce apoptosis-induced cell death 21. We and others have recently investigated the relative contribution of 
each member of the cluster in a mouse model of myc-driven lymphoma 15, 16. miR-19a and miR-19b were 
identified as the key component of the miR-17∼92 cluster in this specific context.  In fact, it was found that they 
largely mediate the pro-survival activity of the cluster by targeting the tumor suppressor protein PTEN, thus 
suppressing apoptosis 15, 16. 
More controversial is the role played by miR-17∼92 during angiogenesis. In 2006 Dews et al. reported that 
miR-17∼92 over-expression increases angiogenesis in a mouse model of colon cancer. This pro-angiogenic 
function has been attributed to the down-regulation of two anti-angiogenic molecules thrombospondin-1 (TSP-
1) and connective tissue growth factor (CTGF) by miR-18 and miR-19 respectively 69. 
Conversely Doebele et al. have recently demonstrated a cell-intrinsic antiangiogenic function mediated by 
individual members of this cluster in endothelial cells 70. The apparent discrepancy between these two findings 
might lie in the different context in which miR-17∼92 is acting (e.g. Tumor vs endothelial cells). A tentative 
model is shown in fig. 4 71. 
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Fig. 4 Proposed roles of miR-17∼92 in angiogenesis (from Kuhnert and Kuo, 2010) 
Tab. 1 microRNA that function as oncogenes and tumor suppressor genes in human cancers (From Croce, 
2009) 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B-cell lymphoma: the Eµ-Myc mouse model 
 
 
About 95% of all lymphomas are of B-cell origin while the remaining 5% originate from T-cell 72. B cell 
development occurs through several stages during which their Ig heavy and light chain genes undergo profound 
genomic rearrangements to produce a functional B-cell receptor (BCR) (Fig. 5). A hallmark of all B-cell 
lymphomas is a reciprocal chromosomal translocation involving one of the Ig loci and a proto-oncogene. As a 
consequence, the oncogene comes under the control of the Ig promoter that determines its deregulated or 
constitutive expression 72. Such translocations often occur as a result of errors during somatic recombination 
events 73. Among several oncogenes whose deregulated expression is known to be relevant for tumorigenesis, 
oncogenic activation of c-Myc, following a chromosomal translocation event, play a major role in Burkitt’s B-
cell lymphomas 74 (Fig. 6). 
c-Myc was originally identified as the cellular counterpart of the viral oncogene v-Myc 75. 
It is broadly expressed during embryogenesis and in high proliferative adult tissues; furthermore is rapidly 
induced upon mitogenic stimuli. C-Myc roles comprise control of cell growth and proliferation, inhibition of 
cell differentiation, cells sensitization to apoptosis 76. Myc overexpression alone is not sufficient to transform 
cells that often need to acquire additional mutations such as loss of tumor suppressor (e.g. PTEN) to overcome 
the apoptotic stimulus triggered by high levels c-Myc 72. PTEN is a haploinsufficent tumor suppressor gene. 
Loss of a single PTEN allele is a frequent event in human cancer that leads to abnormal activation of the pro-
survival AKT/PI3K pathway 77, 78 (Fig. 7).  
In order to study the role of c-myc in B-cell lymphomagenesis, in 1985 Adams et al. developed a transgenic 
mouse model based on overexpression of c-Myc in the B-cell compartment under the control of the B-cell 
specific Ig heavy chain enhancer. Mice carrying the transgene invariably develop lymphomas and die within 4-6 
months 79. 
Fig. 5 B-cell development stages. Mature (naive) antigen-activated B cells that receive signals 
known as ‘T-cell help’ are driven into primary B-cell follicles in secondary lymphoid organs such 
as lymph nodes, where they establish germinal centers. Here they rapidly proliferate (clonal 
expansion) and undergo somatic hypermutation that leads to the introduction of mutations at a high 
rate into the rearranged Ig variable (V)-region genes of the B cells. Mutations that lead to reduced 
affinity of the BCR for antigen cause cells to undergo apoptosis. A few B cells will acquire 
mutations in the BCR that increase their affinity for antigen. A fraction of these B cells undergo 
class-switch recombination and finally differentiate into memory B cells or plasma cells (from 
Kuppers, 2005). 
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Fig. 6 Translocation of c-myc. The c-myc proto-oncogene is translocated from chromosome 8 to the 
immunoglobulin heavy-chain locus (IgH) on chromosome 14 in Burkitt's lymphomas, resulting in abnormal 
c-myc expression (From The Cell: A Molecular Approach. 2nd edition.Cooper GM. Sunderland (MA): 
Sinauer Associates; 2000). 
Fig. 7 Survival signalling through PI3K/AKT. Survival signals (e.g. EGF, PDGF) activate 
phosphatidylinositol 3-kinase (PI3K).Active PI3K generates the 3-phosphorylated lipid 
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3). This leads to recruitment of the kinases 
PDK1, PDK2 and AKT to the plasma membrane. Active AKT interferes with the apoptotic machinery 
by phosphorylating, and thus inhibiting, the proapoptotic BCL2 family protein BAD. Survival 
signalling by AKT is counteracted by the tumour suppressor PTEN, a lipid phosphatase that 
antagonizes the action of PI3K by removing the 3-phosphate from PtdIns(3,4,5)P3. (From Igney and 
Krammer, 2002) 
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Aims of the Thesis 
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In this study we focused our attention on the miR-17∼92 cluster of miRNAs that is often overexpressed or 
amplified in human cancers and has been shown to have an essential function in mammalian development. 
Our main aim was to identify the role played by the different members of the miR-17∼92 cluster in pathological 
(B-cell lymphomas) and physiological (embryonic angiogenesis) events. Previous reports have shown that miR-
17∼92 is a direct target of the transcriptional activator c-Myc and cooperatively acts with it during 
cancerogenesis. In this study we used a mouse model of Myc-driven B-cell lymphoma to shed light on the role 
of each member of the cluster on tumor maintenance, identify the critical targets and clarify the molecular 
mechanism responsible for the enhanced tumorigenicity.  
Mature miRNA sequences are highly conserved among vertebrates. Although it has been shown that the 
interaction between a miRNA and its targets is mainly mediated by the seed sequence, very little is known about 
the role played by the non-seed region during the target recognition process. Our in vitro model provided an 
excellent opportunity to gain insight into the relative importance of the seed and non-seed sequences in respect 
to miRNA function and target(s) specificity. A second aim of our project was to verify how and to what extent 
mutations in the mature miRNA sequence impair the ability of a miRNA to modulate gene expression.  
Several reports have shown that miR-17∼92 has also an important role in regulating angiogenesis in a context-
dependent manner. In fact, a ectopic expression of this cluster in colon cancer cells, has shown to exhibit pro-
angiogenic activity  while other reports have stated that individual members of the cluster exhibit antiangiogenic 
activity when expressed in endothelial cells. We and others have showed that hypoxia is able, in vitro, to repress 
expression of members of the miR-17∼92 and its paralog cluster miR-106a∼363, thus contributing to elevate the 
levels of the pro-angiogenic factor VEGF, a target of the miR-17/20 family. Here we hypothesized that VEGF 
deregulation could contribute to the early embryonic lethality observed in double (miR-17∼92 and miR-
106a∼363/miR-106b∼25) and triple (miR-17∼92/miR-106b∼25/miR-106a∼363) knock out embryos and, with a 
lower penetrance, in miR-17∼92 knockout embryos. By using a genetic loss-of-function approach we sought to 
clarify the role played by miR-17∼92 during physiological angiogenesis and verify whether deregulation of 
VEGF is responsible for the defects in the heart and vasculature pattern development observed in the knock out 
embryos and could contribute to explain their embryonic lethality. 
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Materials and Methods 
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Mouse husbandry 
 
Animal studies and procedures were approved by the Memorial Sloan Kettering Cancer Center Institutional 
Animal Care and Use Committee. Mice were maintained in a mixed 129SvJae and C57/B6 background. The 
Rosa26-Cre-ERT2 and miR-17-92fl/fl mice have been described previously (Ventura et al. 2007, 2008). The Eu-
Myc mice were generated and described by Adams et al. (1985). For the in vivo tumorigenicity studies, 4- to 8-
wk-old athymic (nu/nu) mice were injected intravenously with 10^5 lymphoma cells and monitored daily. Mice 
were euthanized when moribund. Kaplan-Meier curves were plotted using PRISM software, and the log-rank 
Mantel-Cox test was used to determine statistical significance. In vivo fluorescent GFP imaging was performed 
with the Maestro Imaging system (CRI, Woburn, MA USA) 
 
 
Antibodies and immunohistochemistry 
 
The following antibodies (Abs) were used for WB: PTEN antibody (1:2000, Cell Signaling, 138G6, cat #9559), 
tubulin antibody (1:5000, Sigma cat #T9026). VEGF (147) rabbit polyclonal Antibody (1:1000, Santa Cruz 
Biotechnology), GAPDH (6C5) mouse monoclonal antibody (1:1000, Santa Cruz Biotechnology) 
Immunohistochemical staining was performed on 5μm sections of formalin fixed paraffin-embedded tissues, 
using an automated staining processor (Discovery XT, Ventana Medical Systems, Inc.). The PTEN antibody 
was diluted 1:100 in PBS 2%BSA. 20X images from each tumor were acquired with a Nikon Eclipse E400 
microscope connected to a Nikon Digital Slight camera using identical acquisition settings for all samples. 
 
 
RNA blotting 
 
RNA blotting was performed as described 80 using Express-hyb™ Buffer (Clontech, Moutain view, CA) and 
DNA oligonucleotide probes complementary to the mature miRNA sequences. Blots were washed once in 2X 
SSC plus 0.5% SDS, and a second time in 0.2XSSC plus 0.5% SDS at 42 °C such that less than 10% cross-
hybridization was observed. 
 
 
Cell culture and retroviral transduction 
 
The Eµ-Myc; miR-17∼92fl/fl; Cre-ERT2 lymphoma lines were cultured on a feeder of irradiated NIH-3T3 cells in 
a medium composed of 50% DMEM and 50% IMDM, supplemented with 10% fetal bovine serum. To induce 
deletion of the miR-17∼92 cluster, cells were incubated for 4 days with 250 nM 4-OHT. During our initial set of 
experiments with 4-OHT-treated lymphoma cells, we noticed that, upon prolonged passages, the few cells that 
had escaped full miR-17∼92 deletion (miR-17∼92fl/fl and miR-17∼92fl/Δ) invariably outcompeted the miR-
17∼92Δ/Δ cells, eventually becoming the majority within a couple of weeks. To avoid this limitation and allow 
the execution of long-term in vivo experiments, 4 days after 4-OHT treatment, subclones were isolated by 
plating 10 cells per well into a 96-well plate using a MoFlo fluorescence-activated cell sorter. After expansion, 
clones composed solely of fully recombined cells were isolated and used for further manipulation. Retroviruses 
were generated in Phoenix packaging cells. When required, transduced cells were selected by adding puromycin 
(2 mg/mL) to the culture medium for 4 d. 
MCF-7 cells were routinely grown in Gibco DMEM:F12 (Invitrogen, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (FBS), 100 U/ml penicillin, and 50mg/ml streptomycin. Seventy percent confluent cells were 
stimulated with 300 mM CoCl2 for 4 or 24 h. 
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Primary Mouse Embryo fibroblasts (MEFs) were isolated from E13.5 following a standard protocol. MEF were 
cultured in DME-HG supplemented with 10% fetal bovine serum under standard or hypoxic (5%O2) condition 
in the hypoxia incubator HERA cell 150 (Thermo scientific). 
 
 
Plasmids and shRNA library 
 
A 1.2-kb fragment encompassing the entire miR-17∼92 cluster was PCR amplified from mouse genomic DNA 
and cloned into the MSCV-PIG retroviral vector (a gift from Mike Hemann, Massachusetts Institute of 
Technology). Deletion mutants were by site-directed PCR and verified by sequencing. The shRNA library was 
cloned in the MLP retroviral vector (a gift from Michael Hemann, Massachusetts Institute of Technology). For 
each gene, three shRNA directed against the coding sequence were designed using the RNAi Central resource 
created by the laboratory of Greg Hannon (http://katahdin.cshl.org:9331/ siRNA/RNAi.cgi?type=shRNA). Each 
construct was sequence-verified. 
 
 
Luciferase assays 
 
The luciferase reporters constructs containing portion of the PTEN 3’UTR and carrying mutations of the miR-
19 seed matches were a gift of Joshua Mendell (Johns Hopkins University, Baltimore, Maryland) and their 
generation is described in O’Donnell et al., 2005. For transfection, HeLa cells were seeded at a density of 
150,000 cells/well in 24-well plates. The next day, cells were transfected with 100 ng pGL3-PTEN reporter 
(wild-type or mutant), 20 ng of pRL-SV40 (expressing the Renilla luciferase under the control of the SV40 
promoter) and 4ul of a pre-miR-control or pre-miR-19b (6.25 µM, Ambion). Transfections were performed 
using the siPORT NeoFX reagent (Ambion) following manufacturer’s instructions. Early-passages primary 
miR-17~92 +/+ and miR-17~92 Δ/Δ MEFs (described in Ventura et al., 2008), plated at 60% confluency in 24-
well plates, were transfected with 100 ng pGL3-PTEN reporter (wild-type or mutant), 20 ng of pRL-SV40, and 
100 ng of MSCVPIG constructs using FUGENE 6 (Roche) and following manufacturer’s instructions. The 
luciferase reporters constructs containing a portion of the VEGF 3’UTR with a wildtype or mutated miR-17 
binding site were generated according to a standard cloning protocol (Promega). Early-passages primary miR-
17~92Δ/Δ MEFs were plated at a density of 30,000 cell/well in 24 well plates. The next day cells were 
transfected with 100ng psiCHECK-2-VEGF3’UTR reporter (wild type or mutant) and 100 nM pre-miR or a 
negative control (Ambion). Transfections were performed using the siPORT NeoFX reagent (Ambion) 
following manufacturer’s instructions. Firefly and Renilla Luciferase activities were measured 48 hours after 
transfection using the Dual Reporter Luciferase kit (Promega) and a Glomax 96 luminometer (Promega). 
 
 
Apoptosis assays 
 
Apoptosis was measured using the Caspase Detection Kit (Red-VAD-FMK or FITC-VAD-FMK, Calbiochem) 
and confirmed using the TUNEL assay (In Situ Cell Death Detection Kit, TMR red, Roche) following the 
manufacturer’s instructions. 
 
 
Gene expression analysis 
 
Total RNA extracted from three technical replicates was hybridized to the Affymetrix 430 A2.0 gene chip, 
following the manufacturer’s instruction. Gene expression was normalized using the GCRMA Bioconductor 
package, and log expression values were computed using the limma package. 
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For genes with multiple probes, the probe with lowest adjusted P-value was selected. Genes with a log 
expression change of <_0.2 in all three comparisons and with an adjusted P-value < 0.05 in at least one 
comparison were considered for subsequent overlap analysis.  
 
 
Pre-miR and anti-miR transfections 
 
Transfections were performed with either pre-miR or antimiR (Ambion, Austin, TX). MCF-7 cells were seeded 
at 4*10^5 cells/well in six-well plates. MEFs were seeded at 3*10^4 cells/well in 24-well plates. After 24 h 
(30–40% confluency), the cells were transfected with the pre-miR (50 nM) or the anti-miR (100 nM) using 
siPort Neo Fx transfection agent (Ambion), according to manufacturer’s instructions. Non-specific pre-miR and 
anti-miR (Ambion) were used as negative controls together with mock control. The success of transfection was 
confirmed by quantitative real-time PCR. 
 
 
CD-31 (PECAM) whole mount staining 
 
For the PECAM whole mount immunostaining the following protocol was used. Embryos were dissected, fixed 
in 4% cold PBS overnight, dehydrated in increasing methanol concentration and stored at -20°C. The day of 
use, embryos were treated with 6% H202 to inactivate endogenous preoxidases and rehydrated in decreasing 
methanol concentration. Following blocking in 10% goat serum in PBST, embryos were incubated o.n. at 4°C 
with the anti-CD31(PECAM) Rat anti-mouse IgG (BD pharmingen) diluted in blocking solution. The second 
day embryos were washed 3 times for 2hrs with PBS and incubated o.n. at 4°C with a biotynilated goat anti-rat 
IgG (Vectastain kit, Vectorlab). The third day embryos were washed again 3 times for 2hrs in PBS and then 
incubated with streptavidin-HRP (TSA kit, Invitrogen) o.n at 4°C. After a final wash in PBS for 6hrs,  signal 
was dected using the DAB chromogenic substrate. Embryos were cleared in 80% glycerol o.n. at 4°C. 
Alternatively glycerol was washed off with PBS and embryos were cleared with a mixture 1:2 of Benzyl 
alcohol/Benzyl Benzoate. 
 
 
Real Time PCR 
 
Total cellular RNA was isolated using TRIZOL (invitrogen) according to manufacturer’s protocol. For VEGF 
mRNA detection, 1 µg of total RNA was reverse transcribed using the high capacity cDNA archive kit (Applied 
Biosystems), according to vendor’s instructions. VEGF mRNA sequence was detected using the 
Mm01281449_m1 VEGF TaqMan gene expression assay (Applied Biosystems). To normalize quantitative real-
time PCR reactions, parallel reactions were run on each sample for β-Actin. Changes in the target mRNA 
content relative to β-Actin were determined using the comparative Ct method to calculate changes in Ct, and 
ultimately fold and percent change. An average Ct value for each RNA was obtained for replicate reactions. 
 
 
VEGF detection by ELISA 
 
Human and Mouse VEGF protein was measured in conditioned medium or whole organ lysates using the VEGF 
Quantikine ELISA kit (R&D, Systems, Minneapolis, MN) with the lowest detection limit of 5 pg/ml, with intra-
assay precision of<4.8% (or better than 2.5% and<4.8%) and inter-assay precision of<7.2% (or better than 4.7% 
and<7.2%). All points were done in triplicate, and the all the experiments were repeated three times. The range 
of curve standards was 0, 15.6, 31.2, 62.5, 125, 250, 500 pg/ml; all VEGF concentrations in samples were 
within the range of curve standard. Linear regression analysis was performed to create the standard curve. 
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miRNA target predictions  
 
miRNA targets were predicted using miRanda (http://www.microrna. org) and TargetScan 
(http://www.targetscan.org). For the cumulative distribution function (CDF) plots, target sites were restricted to 
perfect seed complementarity between positions 2 and 7 of the miRNA. Empirical cumulative distributions were 
computed using R ecdf function for the set of predicted gene of the transduced miRNAs and for the genes with 
no target sites (background). P-values were computed using the Kolmogorov-Smirnov two-sample test. 
 
 
Statistical analysis 
 
The correlations were studied by Student’s t-test or the one-way ANOVA test for multiple group comparison. P-
values <0.05 were considered statistically significant. 
Genetic and functional dissection of the miR-17∼92 cluster of miRNAs  Dr. Aleco D’Andrea  
 20 
              
Results – Part I 
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Generation of miR-17∼92 flox/flox; Eµ-Myc ; CRE-ERT2 mice 
 
In order to generate an in vivo model where the deletion of the miR17∼92 cluster can be temporary controlled, 
Eµ-Myc mice 79 were crossed to mice carrying a conditional miR17∼92 knockout (KO) allele  (Fig. 1A). The 
resulting mice were further crossed to CRE-ERT2 mice carrying a modified version of the CRE recombinase 
linked to the estrogen receptor T2 (ERT2) that was targeted to the ubiquitously expressed ROSA26 locus 81. The 
ERT2 moiety fused to CRE retains the recombinase in the cytosol until 4-hydroxy-tamoxifen (4-OHT) 
administration releases this inhibition (Fig. 1B). Upon 4-OHT binding the CRE recombinase translocates to the 
nucleus where it can catalyze the recombination between the two loxP  sites and thus deleting the miR-17~92 
cluster. Compared to the previously published studies based on the overexpression of the miR-17~92 cluster, 
our approach is based on the removal of the endogenous miR-17~92 locus and thus is more likely to identify 
physiologically relevant functions of this cluster of miRNAs. 
A lymphoma cell line (named AV4182) was generated and propagated in vitro from these mice. When injected 
into immunocompromised mice those cells were able to form tumors (data not shown). Cells were treated with 
250nM 4-OHT for 4 days to verify efficiency of recombination. Results from genotyping and realtime PCR are 
shown in Fig. 3C and D, confirming efficient deletion of both miR17∼92 alleles and concomitant loss of miR-
17~92 expression. 
 
 
miR-17∼92 suppresses apoptosis in Eµ-Myc lymphomas 
 
 
Next we sought to determine whether removal of the cluster had an effect on the growth of the Eµ-Myc B-
lymphoma cells. Following 4-days of 4-OHT treatment, cells were allowed to recover for 4 additional days to 
exclude any possible adverse effects of sustained CRE expression on the growth of lymphoma cells 82. As 
shown in Fig. 2A deletion of the miR17∼92 cluster drastically reduced the cell growth over the course of 6 days. 
Moreover restoration of miR-17∼92 expression was sufficient to rescue this phenotype (Fig. 2A). Additional 
experiments were conducted to further understand whether a reduction in cell proliferation, an increase in cell 
death or a combination of both were responsible for the different growth kinetics between miR17∼92fl/fl and 
miR17∼92Δ/Δ lymphoma cells. Analysis of cell cycle by BrdU staining showed no difference in cell cycle 
distribution between miR17∼92fl/fl and miR17∼92Δ/Δ cells (Fig. 2B), while levels of active caspases were 
consistently higher in the miR17∼92Δ/Δ cells, as measured by the FMK-VAD caspase specific inhibitor staining 
(Fig. 2C). These results suggest that miR17∼92 expression enhances survival of the lymphoma cells by 
suppressing apoptotic mechanisms. This hypothesis was further confirmed by means of the TUNEL assay (Fig. 
2D). Taken together these results demonstrate that miR17∼92 cluster expression is necessary for the survival of 
the Eµ-Myc lymphoma cells. 
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Fig. 1 CRE-ER-mediated miR-17-92 deletion. A) Schematic of the conditional miR-17~92 KO allele. 
Arrows represent the primers used to detect the floxed and the deleted (Δ) allele. B) Schematic of the CRE-
ERT2 system C) PCR on genomic DNA extracted from Eµ-Myc; miR-17~92fl/fl; Cre-ER lymphoma cells 
mock treated or after four days of 4-OHT treatment. D) Quantitative RT-PCR analysis of the expression of 
miR-17~92 in lymphoma cells before (gray bars) and after (white bars) 4-OHT treatment. Each component 
of miR-17~92 was detected independently and the results normalized relative to the expression observed in 
mock-treated cells. Each experiment was performed in quadruplicate, Error bar = Standard Deviation (SD).  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Fig. 2 miR-17~92 suppresses cell death in Eµ-Myc lymphomas. A) Growth curves of miR-17~92fl/fl 
(black line) miR-17~92Δ/Δ (red line) and miR-17~92Δ/Δ cells infected with a retrovirus expressing the entire 
miR-17~92 cluster (blue line). Error bars=SD of three technical replicates. The plot is representative of three 
independent experiments. B) BrdU incorporation in miR-17~92fl/fl and miR-17~92Δ/Δ lymphoma cells. Cells 
were incubated with BrdU for one hour. Incorporated BrdU was detected with a FITC-conjugated anti-BrdU 
antibody. DNA content was measured by propidium iodide staining. C) Caspase activity in exponentially 
growing miR-17~92fl/fl and miR-17~92Δ/Δ lymphoma cells as detected by flow cytometry using FITC-
conjugated VAD-FMK. The percent of VAD-FMK+ cells is shown. D) TUNEL assay to detect spontaneous 
apoptosis in miR-17~92fl/fl and miR-17~92Δ/Δ isogenic lymphoma cells. 
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Genetic dissection of the miR17∼92 cluster: Role of miR-19 
 
Based on these preliminary results we next decided to genetically dissect the miR17∼92 cluster by determining 
the relative role of its individual components in mediating the oncogenic properties. To this purpose we 
generated a series of mutant alleles each carrying a single miRNA or lacking a whole seed family (Fig. 3A). In 
addition we generated a construct lacking all miRNAs except miR-19a and miR-19b (Fig. 3A). The wild type 
and the mutants alleles were cloned into the MSCV-Puro-IRES-GFP vector, a retroviral vector encoding the 
green fluorescent protein (GFP) and the puromycin resistance gene (Fig. 3B). Considering that the deletion of 
even a single miRNA from the cluster inevitably alters the structure of the primary trancript (pri-miRNAs) and 
could negatively affect the processing or expression of the remaining miRNAs, we first transduced the miR-
17~92Δ/Δ cells and verified the correct expression of the miRNAs for each construct (Fig. 3C, data not shown). 
To determine the ability of each construct to suppress the increased cell death observed in the miR-17~92Δ/Δ 
cells we transduced those cells by titrating the virus to achieve an infection efficiency of 5-30%. We reasoned 
that if reintroduction of the wild-type or mutant alleles is sufficient to rescue the phenotype observed upon 
removal of the cluster, then the fraction of GFP+ cells should increase over time (Fig. 4A). We monitored cells 
for up to 8 days from the time of the infection. As expected, reintroduction of the full-length miR-17∼92 cluster 
determined a strong increase in the fraction of GFP+ cells at day 8 from the infection (Fig. 4B). When 
ectopically overexpressed, the miR-106a∼363 paralog cluster, but not the miR-106b∼25 cluster, also determined 
an increase of the fraction of GFP+ cells over time (Fig.4B, C). Because the miR-106b∼25 cluster lacks two of 
the four seed families, miR-18 and miR-19, we hypothesized that those miRNAs might have a prominent role in 
the context of Eµ -Myc driven B-cell lymphomas. In fact, when we reintroduced each miRNA individually we 
noticed that re-expressing miR-19b was sufficient to phenocopy the miR-17∼92 full-length cluster 
reintroduction while none of the other miRNAs (mir-17, 18, 19a, 20, 92) seemed to have an effect (Fig. 4B). 
This model was confirmed by the observation that the rescuing ability of the miR-17∼92 cluster was completely 
lost only upon deletion of the miR-19 seed family (Fig. 5A, B). Moreover re-expressing the miR-19 seed family 
only (miR-19a and miR-19b) could largely recapitulate the effect seen when reintroducing the whole cluster 
(Fig. 5A, B). Interestingly, the rescuing ability of the miR-19 family alone was slightly lower than the full 
cluster thus suggesting the existence of a certain degree of cooperativity among the different seed families in 
this context. Importantly, we observed a reduction in the number of apoptotic cells following reintroduction of 
miR-19a and miR-19b in these cells (Fig. 5C). 
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Fig. 3 Validation of retroviral constructs. A) Schematic of the miR-17~92 derivatives cloned into MSCV-
PIG. B) the MSCV-Puro-IRES-GFP vector. C) Plots showing the relative expression of each member of the 
miR-17~92 in cells transduced with the indicated retroviral constructs. miR-17~92Δ/Δ lymphoma cells were 
transduced with the indicated retroviruses and treated with Puromycin (2µg/ml) for four days to eliminate 
uninfected cells. After selection, total RNA was extracted and analysed by quantitative RT-PCR to determine 
the relative expression of each member of the miR-17~92 cluster using Taqman probes from Applied 
Biosystem. Internal normalization was to sno-146 (four replicates per sample, error bar = 1 SD). Expression of 
each miRNA is plotted as fold increase relative to cells transduced with the empty vector (gray bars). For 
comparison, in each graph we have included the expression levels of the endogenous miRNAs as detected in 
miR-17~92fl/fl cells (white bars). 
!
"
#$%&'() *+,-
./#
01+01+
23+4!56784!
9-:;<#*.
:
=>?@=A? BC?@=AD AB=E
F3GH@1I'J
!=E<BC
!=>
!=A?K@D
!AB
L@=A?K@D@
23+<=E
23+<=>
23+<=A?
23+<BC?
23+<=AD
23+<AB
Genetic and functional dissection of the miR-17∼92 cluster of miRNAs  Dr. Aleco D’Andrea  
 26 
miR-17~92∆/∆ 
lymphoma cells
Infect with PIG
costructs
Determine fraction of GFP+ cells 
at day 2 and 8 post-infection
rescue
No rescue
miR-19b
GFP
 intensity
GFP
 intensity
miR-17 miR-20
GFP
 intensity
GFP
 intensity
miR-19a
GFP
 intensity
GFP
 intensity
miR-18
GFP
 intensity
C
Construct name miRNAs encoded Rescue
Empty vector - -
       miR-17~92 17, 18a, 19a, 20a, 19b, 92 +++
   miR-106a~363  106a,18b, 20b,19b-2,92-2, 363 ++
miR-106b~25 106b, 93, 25 -
miR-17 17 -
miR-18 18a -
miR-20
 20a -
A
B
miR-106a~363
106a 18b  20b 19b-2 92-2 363
miR-106b-25
miR-92
GFP
 intensity
miR-19a 
 19a -
GFP
 intensity
miR-17~92
17
18a19a 20a19b 92
miR-19b
 19b ++
106b 93 2517
miR-92
 92 -
Fig. 4 miR-19b is the critical oncogenic miRNA in the Eµ –Myc model. A) Schematic of the 
experimental design. B) Histogram overlays of miR-17~92Δ/Δ cells transduced with PIG retroviruses 
expressing the indicated miR-17~92 derivatives. The cells were assayed by flow cytometry to detect GFP 
expression at day 2 (blue plot) and day 8 (red plot) post-infection. A schematic of the miR-17~92 derivative 
used is shown under each overlay. C) Table summarizing the results of the experiments shown in panel B. 
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Fig. 5 MiR-19a and miR-19b mediate the pro-survival and oncogenic functions of miR-17~92 in Eµ-
Myc B-cell lymphomas. A) Histogram overlays of miR-17~92Δ/Δ cells transduced with PIG retroviruses 
expressing the indicated miR-17~92 derivatives. The cells were assayed by flow cytometry to detect GFP 
expression at day 2 (blue plot) and day 8 (red plot) post-infection. A schematic of the miR-17~92 derivative 
used is shown under each overlay. B) Table summarizing the results of the experiments shown in panel B. C) 
Caspase activity in miR-17~92fl/fl and miR-17~92Δ/Δ cells transduced with the indicated PIG constructs. Error 
bar = 1 SD deviation. 
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Deletion of mir-19 affects tumorigenicity in vivo 
 
To determine whether miR-19 is required for the tumorigenicity of the Eµ-Myc B-lymphomas cells in vivo we 
injected a cohort of nude athymic mice with miR-17∼92fl/fl and miR-17~92Δ/Δ lymphoma cells. While 
miR17∼92fl/fl cells invariably formed lymphomas that lead to death within 2–3 weeks, the miR-17~92Δ/Δ cells 
produced lymphomas with a significantly (P < 0.0001) longer latency (Fig. 6A). The tumorigenicity of the miR-
17~92Δ/Δ cells was fully restored by reintroduction of the full cluster (P<0.0001) and, to a lower extent, by re-
expression of miR-19a and miR-19b (Fig.6A, B). Moreover a construct lacking miR-19a and miR-19b did not 
have any effect on the latency (P=0.9816) (Fig.6A, B).  Therefore we confirmed that miR-19 profoundly 
influences the tumorigenicity of the miR-17~92Δ/Δ lymphoma cells. As seen in the in vitro rescue experiment re-
expression of the whole cluster ad a stronger effect than reintroduction of miR-19a and miR-19b only. 
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Fig. 6 miR-19 oncogenic role in vivo. A) Survival analysis of mice injected with of miR-17~92fl/fl and 
miR-17~92Δ/Δ lymphoma cells transduced with the indicated PIG constructs. N = 16 mice for each construct, 
over three independent experiments. B) In vivo GFP imaging showing GFP positive tumors derived from 
injected cells.  
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Identification of miR-19 targets in B-cell lymphomas 
 
The results showed so far confirm a prominent oncogenic role for the miR-19 seed family in the context of Eµ-
Myc driven B-cell lymphomas. We next sought to identify the critical targets of mir-19 by combining 
bioinformatic tools with gene expression analysis data. Algorithm-based miRNA prediction tools such as 
miRANDA, TargetScan, Pictar identify hundreds of possible targets, but many of them are likely to be false 
positive or irrelevant targets. A number of recent reports have shown that mRNA destabilization is the primary 
mechanism through which miRNAs act on their targets, therefore gene expression profiling would allow us to 
identify the majority of true relevant miR-17∼92 targets in our model 5. We compared the gene expression 
profile of the miR-17∼92fl/fl and miR-17∼92Δ/Δ cell lines. To gain additional information, we also profiled 
miR17∼92Δ/Δ cells transduced with constructs expressing miR-17∼92 wild type or miR-19a, b only (Fig. 7A). 
Deletion of miR-17∼92 led to preferential upregulation of genes whose 3’ untranslated regions (UTRs) contain 
binding sites for the miRNAs of the cluster (Fig. 7B, P-value<2.22e-16 Kolmogorov and Smirnov test). 
Accordingly, ectopic expression of miR-17∼92 in miR-17∼92Δ/Δ cells led to the preferential down-regulation of 
miR-17∼92 targets (Fig. 7C left panel, P-value < 2.22e-16 KS test). Finally, reintroduction of miR-19a and 
miR-19b only selectively affected mRNAs carrying binding sites for these two miRNAs (P-value = 6.35e-15), 
but not genes with binding sites for the other members of the miR-17∼92 cluster (Fig.7C, right panel). 
A total of 568 genes were identified whose expression was upregulated (log2 expression change >0.20) by 
removal of the endogenous miR-17∼92 locus and downregulated by the reintroduction of the full miR-17∼92 
cluster or miR-19a, b only (Fig. 7D). Among them 95 genes contained at least one mir-19 binding site in their 
3’UTR and were chosen for further analysis (Tab. 1). In an effort to identify those targets directly linked to the 
phenotype observed the list of genes was further narrowed down to 46 genes (Fig. 8B, Tab.1). We reasoned that 
if miR-19 promotes survival by repressing the expression of one or more of these genes, their knockdown by 
RNAi should at least partially phenocopy miR-19 reintroduction. To test this hypothesis we designed three 
shRNA for each of the 46 genes and cloned them into the MLP vector (Fig. 8A), a retroviral vector expressing 
GFP. The experimental design was similar to that described in Fig. 4A. Briefly each construct was individually 
transduced into the miR-17∼92Δ/Δ lymphoma cells and the viral preparations were titrated to achieve an 
infection efficiency of 5-30%. The fraction of GFP+ cells was measured at 2 and 11 days after the infection. As 
shown in Fig. 8C, for the majority of shRNAs the number of GFP+ cells did not change over time or was 
slightly lower at day 11 indicating that the expression of that shRNAs did not provide any growth advantage or 
was detrimental, respectively. However, for some of shRNAs we observed a significant increase in the fraction 
of GFP+ cells at day 11 suggesting that they were positively affecting the growth of the tumor cells. Among 
them, two of the three shRNAs against PTEN had the stronger effect, largely phenocopying the ectopic 
expression of miR-19a/b (Fig. 8C). Moreover a number of other shRNAs had a more modest but still significant 
effect. In particular all three shRNAs directed against Sbf2 and two out of three directed against Bcl7a and 
Rnf44 scored positive suggesting that these genes might contribute to the pro-survival functions of miR-19. 
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Fig. 7 Gene expression profiling identifies miR-19 targets in Eµ-Myc lymphoma cells. A) Description 
of the various lymphoma cells generated for the gene expression analysis experiments. B) Differences in 
mRNA levels between miR-17~92fl/fl and miR17∼92Δ/Δ lymphoma cells transduced with empty PIG vector 
were monitored with microarrays. Cumulative distribution functions (CDF) plots are shown for: mRNAs 
that do not contain miR-17~92 seed matches in their 3’UTRs (black line), mRNAs containing one or more 
seed matches for miR-19 in their 3’UTR (red line) and for mRNAs containing one or more seed matches for 
either miR-17, miR-20a, miR-18a or miR-92 (blue line). In the absence of endogenous miR-17~92 
expression, a statistically significant upregulation (p-value<2.22e-16, KS-test) is observed for the predicted 
miR-17~92 targets relative to the background gene population. C) CDF plots of the changes in mRNA 
expression levels between miR17∼92Δ/Δ + PIG-miR-17~92 and miR17∼92Δ/Δ lymphoma cells (left panel) 
and between miR17∼92Δ/Δ + PIG-miR-19a, b and miR17∼92Δ/Δ lymphoma cells (right panel). Figure legend 
is as in panel B. A significant downregulation is observed for mRNA with predicted miR-17~92 targets (left 
panel) and for genes with only miR-19 in the case of PIG-miR-19a,b and miR17∼92Δ/Δ (right panel). D) 
Venn diagram summarizing the overlap in gene expression changes observed between the various 
transduction experiments. E) As in panel D), but the analysis was limited to mRNAs whose 3’-UTR 
contains at least one predicted binding site for miR-19 (according to TargetScan 5). 
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Tab. 1 This table includes the 95 genes from the interesection of the Venn diagram shown in figure 7E. Each 
gene contains at least one conserved miR-19 binding site in its 3'-UTR according to TargetScan 5.1 (Column 
I) and shows a log2 fold change<-0.2 in each of the three comparisons (columns B, D and F). The adjusted 
p-value is also shown (columns C, E and G). In red are indicated the genes that were selected for the in vitro 
RNAi screen and functional validation.  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Fig. 8 An in vitro RNAi screen to identify functionally relevant miR-19 targets. A) The MLP  
retroviral vector B) List of 46 miR-19 genes assayed in the in vitro shRNA screen. Genes for whom 
at least two distinct shRNAs scored positive in the assay are shown in bold. C) Scatter plot 
summarizing the result of the screen. Each dot represents an individual shRNA construct where the 
x-axis is the percentage of GFP cells at the beginning of the experiment (two days after infection) 
and the y-axis is the percentage of GFP cells eleven days later. The green dot identifies the empty-
vector control. shRNAs that scored positive in the screen are highlighted in red and labeled. Dots 
corresponding to genes for which at least 2 out of three shRNAs provided significant growth 
advantage are labeled. PIG-miR-19a/b was included in the screen as positive control and for 
comparison (blue dot).  
ShRNA screening summary
REFSEQ Gene symbol
 NM_026825 Lrrc16a
 NM_145486 March2
 NM_011519 Sdc1
 NM_144516 Zmynd11
 NM_011361 Sgk1
 NM_147201 Nrbp1
 NM_027453 Btf3l4
 NM_013876 Rnf11
 NM_001033277 Spryd3
 NM_027445 Rnf167
 NM_001103182 Lin9
 NM_007715 Clock
 NM_026967 Rhebl1
 NM_133673 Tor1b
 NM_029850 Bcl7a
 NM_001039482 Klhl20
 NM_033560 Vps37a
 XM_911187 Nbeal2
 XM_001477215 Sbf2
 NM_025793 Wdr45l
 NM_001102430 Arfgef1
 NM_001080798 Aff1
 NM_134064 Rnf44
REFSEQ Gene symbol
 NM_009372 Tgif1
 NM_001081323 Mphosph9
 NM_212484 Cnot6 
 NM_016670 Pknox1
 NM_024454 Rab21
 NM_001103179 Brwd1
 NM_010496 Id2
 NM_010432 Hipk1
 NM_001113248 Sin3b
 NM_145150 Prc1
 NM_010028 Ddx3x
 NM_178606 Reep3
 NM_199196 Suz12
 NM_175258 Rapgef6
 NM_001042541 Akap1
 NM_033604 Rnf111
 NM_011135 Cnot7
 NM_173185 Csnk1g1
 NM_008960 Pten
 NM_001038018 Grk6
 NM_144910 Cnot6l
 NM_001042558 Apaf1
 NM_153198 Hbp1
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PTEN is a direct miR-19 target 
 
 
PTEN is one of the most frequently mutated tumor suppressor genes in human cancers, it is an haploinsufficient 
tumor suppressor gene and monoallelic mutations at this locus are observed in >50% of sporadic tumors 77. In 
mice loss of a single allele dramatically increase incidence of a variety of tumors, including T-cell lymphomas, 
as well as tumors of endometrium, liver, prostate, gastrointestinal tract, and thyroid 83. PTEN negatively 
regulates cell proliferation by inhibiting the PI3K/AKT pathway. Specifically, PTEN is a phospholipid 
phosphatase that antagonizes the phosphatidylinositol-3-kinase (PI3K) pathway by hydrolyzing the 3-phosphate 
on phosphatidylinositol 3,4,5-trisphosphate (PIP3), a second messenger that promotes cell growth and survival, 
to generate phosphatidylinositol 4,5-bisphosphate (PIP2) 77. In conclusion, a number of experimental 
observations indicate that even a minor impairment in PTEN function can lead to the development of cancer, 
suggesting that modest modulation of its levels by miRNAs may have important functional consequences. 
The PTEN 3’UTR contains two conserved miR-19 binding sites (Fig. 9A) and it has previously been shown to 
be a direct miR-19 target 17, 21, 65. Here we first confirmed that miR-19 directly acts on the PTEN 3’UTR by 
performing a luciferase reporter assay in both HeLa cells and miR-17∼92+/+ and miR-17∼92Δ/Δ primary mouse 
embryo fibroblasts (Fig. 9B). Both western blot (Fig. 9C) and immunohistochemistry (Fig. 9D) confirmed a 
consistent upregulation of PTEN upon removal of the miR-17∼92 cluster. Importantly reintroduction of the full-
length cluster or miR-19a, b only, but not of miR-17∼92Δ19a, b, was sufficient to restore normal PTEN expression 
levels (Fig. 9D, E). In addition, analogous to miR-19 reintroduction, PTEN knockdown also determined a 
reduction in the number of apoptotic cells to the levels observed in the miR-17∼92fl/fl cells (Fig. 9E). 
 
 
PTEN knockdown affects tumorigenicity in vivo 
 
 
Finally we examined whether PTEN knockdown could phenocopy miR-19 reintroduction in vivo. To this 
purpose we injected a cohort of nude mice with miR-17∼92Δ/Δ; sh-PTEN lymphoma cells. As shown in Fig. 10, 
mice injected with miR-17∼92Δ/Δ; sh-PTEN lymphoma cells develop aggressive lymphomas with a latency 
similar to that observed in mice injected with miR-17∼92Δ/Δ cells ectopically expressing miR-19a/b. Again the 
survival was slightly longer compared to control mice injected with miR17∼92fl/fl cells (P=0.0002), suggesting 
the existence of additional targets and/or cooperative mechanisms possibly involving the other members of the 
cluster. 
 
 
Fig. 10 PTEN knock-down phenocopy miR-
19b reintroduction in vivo. Kaplan-Meier 
survival curve of mice injected with miR-
17∼92Δ/Δ lymphoma cells transduced with 
retroviruses expressing shRNAs against PTEN. N 
= 10 (5 mice for shPTEN-1 and 5 mice for 
shPTEN-2). For comparison, the survival curves 
of mice injected with miR-17~92fl/fl, miR-
17∼92Δ/Δ and miR17∼92Δ/Δ + miR-19a, b from 
figure 6A are also included.  ! "! #! $! %! &!!#!
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Fig. 9 Pten is a functionally relevant miR-19 target in B cell lymphomas. A) Schematic representation of 
the Pten 3’UTR with the location of the predicted binding sites for members of the miR-17~92 cluster. 
Sequence alignments between miR-19b and its two predicted binding sites are also shown. B) Luciferase 
reporter assays on Hela cells and MEFs transfected with a reporter plasmid expressing the firefly luciferase 
cDNA fused to a fragment of the PTEN 3’UTR containing the two putative miR-19 sites (pink bars) or 
carrying mutations in both sites (blue bars). Hela Cells were cotransfected with either a pre-miR-control or 
with pre-miR-19b. MEFs were cotransfected with the indicated PIG constructs. For internal normalization, 
each transfection included 20 ng of a plasmid encoding for the Renilla luciferase. Cells were assayed 48 hrs 
later. For comparison the ratio renilla/firefly luciferase measured in cells transfected with the wild-type 
3’UTR was set to 1. Error bar is the standard deviation of triplicates. C) PTEN Western blot on whole cell 
lysates of B-lymphoma cells transduced with the indicated PIG constructs. For comparison, lysates from 
miR-17∼92Δ/Δ cell expressing the two PTEN shRNAs that scored positive in the in vitro screen were also 
assayed (lanes 8 and 9). D) PTEN immunohistochemistry on lymphoma sections obtained from mice 
injected with miR-17~92fl/fl and miR-17∼92Δ/Δ B-lymphoma cells transduced with the indicated miR-17~92 
derivatives (objective = 20X). Brown staining indicates PTEN signal. Slides were processed by automated 
immunostaining and the images collected under identical acquisition conditions. E) Knockdown of Pten 
suppresses apoptosis in miR-17∼92Δ/Δ cells. Apoptosis was measured by detecting caspase activity in miR-
17~92 fl/fl and miR-17∼92Δ/Δ cells transduced with the indicated retroviruses. 
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The oncogenic potential of miR-19b resides in the seed sequence 
 
The results shown above strongly support the idea that one miRNA of the cluster, miR-19b, is of a particular 
relevance in the context of Myc driven B-cell lymphomas. The mature miRNA sequence is made of two 
structural components: the seed region (nt. 2-8) through which the miRNA interacts with their targets and the 
non-seed region, extending from nt. 9 to ~23. The non-seed region frequently participates to the target 
recognition process by providing additional 3’ pairing regions 1, 84. Interestingly, mature miRNAs sequences are 
highly evolutionary conserved suggesting that both the seed and non-seed region are somehow essential and 
both contribute to create a perfectly functional miRNA 1. To experimentally determine the relative importance 
of the seed and non-seed regions of miR-19b,  we next asked whether substituting the non-seed region affects 
the ability of miR-19b to enhance survival of the tumor cells. In our growth competition experiment (Fig. 4B) 
miR-20a, another member of the miR-17~92 cluster, was shown to have very little or no effect on the growth of 
tumor cells. Therefore, we decided to generate two new chimeric constructs, named miR-19b:20 and miR-
20:19b, by exchanging the miR-19b non-seed sequence (nt. 9-21) with that of miR-20 (Fig. 11A). We cloned 
the two chimeric constructs into the MSCV-Puro-IRES-GFP vector and verified that they were correctly being 
expressed by northern blot (Fig. 11B). This is an essential control as modifying the structure of the pri-miRNA 
could in principle alter the processing events that lead to the production of the mature miRNA. By using the 
same experimental approach shown in Fig. 4B and 5B, we reasoned that if the non-seed region is required for 
the miRNA to exert its biological function then the two chimeric constructs should provide little or no growth 
advantage to the cells. Following transduction cells were monitored over the course of ten days for increase in 
the GFP+ fraction of cells. Surprisingly, the miR-19b:20 chimeras could fully recapitulate the effect seen when 
re-expressing miR-19b in the miR17∼92Δ/Δ lymphoma cells (Fig. 11C bottom left panel). Accordingly, the miR-
20:19b chimeras, equally to miR-20, was not able to rescue the growth defect (Fig. 11C, bottom right panel).  
Based on these experiments we conclude that the oncogenic properties of miR-19b are mainly mediated by the 
seed sequence. 
 
 
Mutations in the seed sequence affect miR-19b function 
 
To further investigate the role of the miR-19b seed sequence in suppressing cell-death, we performed a 
systematic mutational analysis. We introduced single point mutations in the seed sequence of miR-19b starting 
from position 2 to position 8, substituting each base with its complementary one and cloned the resulting 
constructs into the MSCV-Puro-IRES-GFP vector (Fig. 12A). We repeated the growth rescue experiment by 
infecting the miR17∼92Δ/Δ lymphoma cells with our miR-19b wild-type and mutant constructs and checked for 
an increase in the GFP+ fraction of cells over the course of ten days. As expected, none of the seed mutants was 
able to rescue the growth of the B-lymphoma cells to the same extent of the wild-type miR-19b (Fig. 12B). 
However a moderate effect was observed for mutations in position 5 and 8 of the miR-19b seed sequence 
possibly reflecting a partial loss of binding specificity or affinity towards targets. In conclusion, the experiment 
described so far showed that the seed sequence is the critical determinant of miR-19b oncogenicity. 
Furthermore, analysis of the gene expression profiles is required to determine whether loss of PTEN repression 
can fully explain the observed phenotype. 
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Fig. 11 The oncogenic properties of miR-19b are specified by the seed sequence. A) Schematic 
representation of the two chimeric constructs obtained by swapping the miR-19b and miR-20 non-seed 
sequences. B) Northern blot on 15 ug of total RNA from the mir-17-92Δ/Δ cells transduced with the 
chimeric constructs. C) Histogram overlays of miR-17∼92Δ/Δ cells transduced with PIG retroviruses 
expressing either the wild type miR-19b/miR-20 or the chimeric miRNAs. The cells were assayed by 
flow cytometry to detect GFP expression at day 2 (red plot) and day 10 (blue plot) post-infection. A 
schematic of the miR-17~92 derivative used is shown under each overlay. 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Fig. 12 Mutations in the seed sequence impair miR-19b function. A) Schematic of the miR-19b seed 
mutant allele series. The seed sequence is shown in bold, the mutated base is highlighted in red. B) 
Histogram overlays of miR17∼92Δ/Δ cells transduced with PIG retroviruses expressing the indicated 
miR-19b derivatives. The cells were assayed by flow cytometry to detect GFP expression at day 2 (red 
plot) and day 10 (blue plot) post-infection. A schematic of the miR-19b derivative used is shown under 
each overlay. The wild-type miR-19b allele was included for comparison. 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Results – Part II 
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Effects of miR-20b on VEGF expression 
 
 
In our preliminary study we investigated the role of the miR-17 family in regulating the angiogenic factor 
VEGF. Oxygen deficiency is proven to stimulate VEGF production leading to increased angiogenesis in tumors 
85, 86. Tumors-induced blood vessel growth is essential for cancer progression as it sustains tumor expansion and 
allow cells to escape from the primary tumors through the blood stream and metastasize 48. Since miR-20b, a 
member of the miR-17 family, has been suggested to act as a negative regulator of VEGF in nasopharyngeal 
carcinoma epithelioid (CNE) cells 50, we set out to study the effects of this miRNA on VEGF expression in 
breast cancer cells under hypoxia. VEGF intracellular protein levels were reduced in pre-miR-20b transfected 
cells by 2.5-fold related to untransfected cells (Fig. 13A). Stimulation with CoCl2, an hypoxia-mimetic agent for 
4 or 24 h increased intracellular VEGF protein levels by 2.9- and 2.7-fold, respectively (Fig. 13A). However, 
transfection of MCF-7 cells with pre-miR-20b, reduced a 4 h CoCl2-induced stimulation of VEGF protein by 
3.3-fold (Fig. 13A). In cells treated with CoCl2 for 24 h, pre-miR-20b inhibited VEGF intracellular protein 
levels by 2.7-fold (Fig. 13A). The effects of miR-20b on the secreted VEGF protein mirrored the above 
findings. As expected, CoCl2 treatment for 4 and 24 h induced extracellular VEGF protein by 60% and 105%, 
respectively (Fig. 13B). Consistent with previous results, transfection with pre-miR-20b inhibited 4 and 24 h 
CoCl2-mediated induction of extracellular VEGF by 30% and 25%, respectively, relative to negative control , 
while basal level of secreted VEGF were reduced by 32% (Fig. 13B). In further validate the impact of miR-20b 
on VEGF expression, we used a synthetic oligonucleotide (anti-miRs) designed to target the mature forms of 
miR-20b and thereby inhibit their expression. Following miR-20b silencing, intracellular VEGF proteins levels 
increased by 1.5-fold (Fig. 13C), while the amount of secreted VEGF were elevated by 20% (Fig. 13D). Taken 
togheter these results suggest that VEGF is, indeed, a true miR-17~92 target in human breast cancer. 
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Fig. 13 VEGF protein levels are decreased by transfection with pre-miR-20b and increased by miR-
20b silencing. A) The abundance of VEGF total protein was determined by WB in 120 µg of total proteins, 
as decribed in Materials and Methods Section. The graph represents the increase of VEGF protein levels 
relative to untrasfected cells±SD; columns, mean; bars, SD. *P < 0.05, control versus pre-miR-20b; **P < 
0.05, control versus CoCl2; §P < 0.05, CoCl2 versus miR-20b+CoCl2. B) The secreted protein levels were 
determined by ELISA. A total of 7*10^5 MCF-7 cells were treated as described Materials and Methods 
Section. The concentrations represent pg of VEGF/ml of conditioned medium from 4*10^5 cells. C) The 
abundance of VEGF proteins was studied by WB in 120 µg of total proteins in MCF-7 cells transfected with 
synthetic oligonucleotides targeting miR-20b (anti-miR-20b) or with negative control anti-miR molecules, 
as described in Materials and Methods Section. The graph represents the increase of VEGF protein levels 
relative to negative control+SD; columns, mean; bars, SD. * P < 0.05 control versus anti-miR-20b. D) The 
concentration of secreted VEGF was measured by ELISA in cells transfected with anti-miR20b or with 
negative control anti-miR. The concentrations represent pg of VEGF per ml of conditioned medium from 
4*10^5 cells. 
Genetic and functional dissection of the miR-17∼92 cluster of miRNAs  Dr. Aleco D’Andrea  
 41 
 
Defective angiogenesis in the miR-17∼92 family knockout embryos 
 
 
VEGF levels are tightly regulated during embryo development 45. In particular, a 2-3 fold VEGF 
overexpression, following removal of the entire 3’UTR from the messenger RNA, has been shown to impairs 
embryo development at early stages (13.5-14.5) due to cardiovascular defects 43. Despite they can often 
complete development and die at birth, ∼60% of the miR-17∼92 single knockout embryos and ~80% of the 
double knockout embryos (DKO, miR-17~92Δ/Δ; miR-106a~363Δ/Δ) prematurely die around E14.5 showing a 
phenotype similar to that described by Miquerol et al. in 2000. As threshold levels of VEGF are extremely 
important during embryonic development we hypothesized that the deregulation of the VEGF signaling pathway 
is, at least partially, responsible for the early embryonic lethality observed in those embryos and that 
combinatory deletion of the miR-17∼92 and miR-106a~363 cluster could in fact facilitate crossing this 
threshold. As shown in Fig. 14A no obvious phenotype is seen in the miR-17~92Δ/Δ; miR-106a~363Δ/y (DKO) 
embryos until E11.5 except for a slight reduction in body size compared to wild type embryos.  Transversal 
sections throughout the embryonic heart at ∼E12.5 reveal the presence of a ventricular septal defect and a 
thinner compact layer of the myocardium (Fig. 14B). By day 13.5 the embryos become edematous with 
extensive hemorrhagic areas, features strictly linked to heart failure and defective blood circulation. Embryos 
invariably die around E14.5 (Fig. 14A). As VEGF signaling is also known to control vascular development 
during embryogenesis 44, we sought to visualize the embryonic vascular pattern by means of the CD-31 staining 
(PECAM), a surface molecule highly expressed in both embryonic and adult endothelial cells (Fig. 14C). By 
comparing the gross appearance of the WT and DKO embryos at E12.5 we observed a clear loss of structural 
organization in the vasculature of the latter. A closer look revealed defects in the intersomitic vessels formation 
(Fig. 14D, E). The intersomitic blood vessels appeared to be discontinuous in the mutants particularly in the 
caudal region  (Fig. 14E). This is in contrast to the organized intersomitic blood vessels observed in a control 
littermate (Fig. 14D). Moreover they failed to correctly fuse along the medial surface of the somites to form the 
vertebral arteries (Fig. 14C, D and Fig. 14F, G). Finally we noticed a consistent increase in vessels density and 
number of branching points in the vasculature of the head (Fig. 14H, I). 
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Fig. 14 Defective heart development and angiogenesis in the miR-17 family of miRNAs Knockout 
mice. A) miR-17~92+/+;miR-106a~363+/y and miR-17~92Δ/Δ; miR-106a~363Δ/y (DKO) embryos at various 
developmental stages. B) Hematoxylin staining of transversal sections of WT and DKO hearts at E12.5. The 
asterisk indicates the ventricular septal defect; the arrow indicates the thinner compact layer of the 
ventricular wall. C) CD-31 (PECAM) whole mount immunostaining of WT and DKO E12.5 embryos. D, E) 
High magnification images of the tail region of WT and DKO E12.5 embryos. Arrow indicates the 
intersomitic vessels; arrowhead indicates the posterior region of vertebral artery. F, G) High magnification 
images of the dorsal thoracic spine region of WT and DKO E12.5 embryos. Arrow indicates the vertebral 
artery. H, I) High magnification images of the right lateral head region of WT and DKO E12.5 embryos.  
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VEGF levels are increased in the miR-17∼92 KO embryos 
 
Next we verified whether miR-17∼92 deletion led to derepression of VEGF expression in the knockout 
embryos. Several primary mouse embryo fibroblast (MEF) cell lines were derived from miR-17∼92+/+, miR-
17~92Δ/+, miR-17~92Δ/Δ embryos at E13.5. Single Knockout embryos with a more severe phenotype were 
selected, as judged by the presence of edemas and hemorrhages in the body. No obvious difference was 
observed in the growth kinetics of the various MEF cell lines when cultured in vitro (data not shown). Levels of 
secreted VEGF were then measured through an enzyme-linked immunosorbent assay (ELISA) specifically 
recognizing the 164aa. isoform of VEGF. As shown in Fig. 15A, under normoxic conditions levels of VEGF 
were ∼3 and ∼7 fold higher in the miR-17~92Δ/Δ MEFs compared to the miR-17~92Δ/+ and miR-17∼92+/+ MEFs, 
respectively. Moreover we cultured the cells under mild hypoxic condition (5% O2) that closely resembles 
physiological oxygen levels found in embryos 87. VEGF secretion was correctly induced and ∼2 fold higher in 
the miR-17~92-/- MEFs compare to the miR-17~92+/+ cells (Fig. 15A). Consistent with the ELISA results, we 
observed a ∼2 fold increase in the levels of VEGF mRNA in the miR-17~92Δ/Δ compared to the miR-17∼92+/+ 
under both normoxic and mild hypoxic conditions (Fig. 15B). These findings prompted us to investigate 
whether VEGF was also upregulated in vivo. Indeed, the levels of VEGF mRNA in the embryo limb, a region 
known to be highly vascularized and actively proliferating at this stage (E13.5), were 40% higher in the 
knockout embryos compared to the wild-type ones (Fig. 15C). Finally we measured the levels of cytoplasmic 
VEGF in whole organ lysates from E13.5 embryos. VEGF was slightly higher in the head of the knockout 
embryos (1.3 fold) and strongly induced in the liver (4 fold) and lungs (9 fold) compared to miR-17~92+/+ 
embryos (Fig. 15D). Noteworthy, the embryonic lung and liver are two of the highest vascularized organs. Thus 
we concluded that miR-17∼92 knockout embryos have increased levels of the pro-angiogenic factor VEGF and 
this upregulation could be responsible for the cardiovascular and angiogenetic defects described earlier in this 
manuscript. 
 
 
VEGF is not a direct miR-17∼92 target 
 
In order to determine whether VEGF upregulation is a direct consequence of the absence of the miR-17∼92 
cluster we transduced a miR-17~92Δ/Δ MEF cell line with the full length miR-17∼92 cluster or a series of mutant 
alleles lacking respectively the miR-17, 19 and 92 miRNA family or expressing the miR-19 family only. We 
first verified that these constructs were correctly expressing the desired miRNAs by Real-time PCR (data not 
shown) and then measured the levels of secreted VEGF upon reintroduction of the different constructs. We 
found that, both in normoxia and at 5%O2, secreted VEGF levels were slightly decreased by restoration of the 
miR-17∼92 full-length cluster expression but not by a construct lacking the miR-17 family (Fig. 16A). 
Nevertheless VEGF levels were still consistently higher than those observed in miR-17~92+/+ MEFs (Fig. 16A) 
indicating that, in MEFs, miR-17∼92 absence is only partially responsible for the upregulation of VEGF. 
Targetscan 88 analysis identified a conserved miR-17 binding site in the mouse VEGF 3’UTR (position 161-
167). A 314 bp region comprising the miR-17 binding site was cloned downstream of the firefly luciferase gene 
into the psiCHECK-2 vector. The miR-17~92Δ/Δ MEFs were transfected with the resulting VEGF3’UTR-
psiCHECK-2 vector together with a single miRNA of the cluster (miR-17, 18, 20, 19b and 92). The luciferase 
reporter assay confirmed that VEGF is not a direct miR-17∼92 target as none of the miRNAs, including miR-17 
and miR-20, were able to modulate firefly luciferase expression  (Fig. 16B).  
In conclusion the miR-17 family does not directly target VEGF in mouse. VEGF upregulation might be instead 
a consequence of the oxygen deficiency caused by a defective fetal blood circulation. 
Genetic and functional dissection of the miR-17∼92 cluster of miRNAs  Dr. Aleco D’Andrea  
 44 
  
m
iR-
17
92
+/+
m
iR-
17
92
/+
m
iR-
17
92
/
m
iR-
17
92
+/+
m
iR-
17
92
/+
m
iR-
17
92
/
0
100
200
300
400
500
600
Normoxia
5% O2  24 hrs
p =0.0083
p =0.0148
ANOVA
p=0.0047
ANOVA
p=0.0242
VE
GF
 
c
o
n
c
e
n
tr
a
tio
n
 
(pg
/m
l)
A
D
m
iR-
17
92
 +
/+
m
iR-
17
92
+/
m
iR-
17
92
/
0
10
20
30
40
VE
FG
 
Co
n
ce
tn
ra
tio
n
 
pg
/m
L 
pe
r 
m
g 
pr
o
te
in
m
iR-
17
92
 +
/+
m
iR-
17
92
+/
m
iR-
17
92
/
0
50
100
150
VE
FG
 
Co
n
ce
tn
ra
tio
n
 
pg
/m
L 
pe
r 
m
g 
pr
o
te
in
B
C
miR-17 92 +/+ miR-17 92 /
0
2
4
6
8
10
Normoxia
5% O2 24 hrs.
VE
GF
 
m
R
N
A 
re
la
tiv
e
 
e
xp
re
ss
io
n
E13.5 HEAD E13.5 LIVER
m
iR-
17
92
 +
/+
m
iR-
17
92
+/
m
iR-
17
92
/
0.0
0.5
1.0
1.5
2.0
VE
GF
 
m
R
N
A 
re
la
tiv
e
 
e
xp
re
ss
io
n E13.5 LIMB
m
iR-
17
92
 
+/+
m
iR-
17
92
+/
m
iR-
17
92
/
0
50
100
150
VE
FG
 
Co
n
ce
tn
ra
tio
n
 
pg
/m
L 
pe
r 
m
g 
pr
o
te
in
E13.5 LUNG
Fig. 15 VEGF is upregulated in the absence of miR-17~92. A) Secreted VEGF levels in miR-17~92+/+, miR-
17~92Δ/+ and miR-17~92Δ/Δ of primary MEFs as determined by ELISA. Each dot of the scatter plot represents a 
different cell line. Error bar= 95% C.I. p< 0.01 for comparison between WT and KO MEFs in normoxia; p<0.05 
for comparison between WT and KO MEFs under 5%O2 . p=0.0047 and p=0.0242 under normoxia and 5%O2 
respectively for multiple group comparison with the one-way ANOVA test. B) Relative expression levels of the 
VEGF mRNA were measured by Real-time in miR-17~92+/+ and miR-17~92Δ/Δ embryos under normoxic and 
hypoxic (5% O2) conditions. For comparison VEGF mRNA levels in WT MEFs under normoxia were set to 1. 
Columns, mean. Bars=SD. P<0.01 for comparison between miR-17~92 WT and KO cells. C) Relative VEGF 
mRNA expression levels in miR-17-92 WT and KO E13.5 embryos. RNA was extracted from the right posterior 
limb. Expression levels in the WT embryos were set to 1. Columns, mean; bars=SD. P=<0.01 for comparison 
between WT and KO embryos. C) Cytosolic VEGF levels in the head, lungs and liver whole organ lysates from 
miR-17~92+/+, miR-17~92Δ/+ and miR-17~92Δ/Δ E13.5 embryos measured by ELISA. Columns, VEGF mean 
concentration (pg/mL) per mg of protein; bars=SD. P<0.05 for comparison between +/+ and -/- embryos. 
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Fig. 16 miR-17-92 does not target VEGF. A) Secreted VEGF levels, upon reintroduction of different PIG 
constructs in miR-17~92Δ/Δ; p53-kd immortalized MEFs, were measured by ELISA. Columns, mean; Error 
Bars, SD B) Luciferase reporter assays on miR-17~92Δ/Δ; p53-kd MEFs transfected with a reporter plasmid 
expressing the firefly luciferase cDNA fused to a 314bp fragment of the VEGF 3’UTR containing a putative 
miR-17 binding site (green bars) or carrying a mutation  (blue bars) and a Renilla firefly luciferase gene for 
internal normalization. Cells were cotransfected with a pre-miR-control or with the pre-miR-17, 18, 20, 19b 
and 92. For comparison the ratio Firefly/Renilla luciferase measured in WT MEFs transfected with the wild-
type 3’UTR was set to 1. No significant difference was observed. 
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Discussion and Conclusions 
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PART I 
In this study we identified miR-19 as the key mediator of the oncogenic properties of the miR-17~92 cluster in 
the context of Myc-driven B-cell transformation. Consistent with initial studies by He et al. we confirmed that 
miR-17~92 cooperates with c-Myc in accelerating lymphomagenesis. Over-activation of the c-Myc pathway is 
known to elicit a strong proliferative effect but also to sensitize cells to apoptosis 76. Although mir-17~92 has 
been shown to promote cell proliferation in other cellular contexts 23, 24, removal of the mir-17~92 cluster did 
not affect cell proliferation in the Eµ-Myc model. c-Myc driven activation of the cluster rather protected the 
tumor cells from apoptosis, as removal of the cluster caused a strong increase in the number of cells undergoing 
programmed cell death. By genetically dissecting the various components of the cluster we showed that only 
members of the mir-19 family can suppress apoptosis.  
The tumor suppressor PTEN was identified as the critical miR-19 target. PTEN is a haploinsufficient tumor 
suppressor gene, giving that lost of even a single allele promotes malignant transformation 77.  Functionally 
PTEN is a lipid phosphatase that negatively regulates the pro-survival PI3K/AKT signaling pathway 78. It has 
previously been identified as a target of mir-17-92 in cell culture-based experiments 17, 21 but how individual 
mir-17-92 components contribute to repress PTEN and, more importantly, whether the downregulation of PTEN 
by mir-17~92 has any functional impact on cell survival in a tumorigenic setting was yet to be proven. Here we 
provide strong evidences that PTEN is a direct mir-19 target and that knockdown of PTEN can phenocopy miR-
19 expression, restoring the tumorigenicity of the miR-17-92 deleted Eµ-Myc lymphoma cells.  A recent report 
also confirmed our findings and extended them to Notch1-induced T-cell leukemias showing that the 
importance of miR-17~92 is not confined to the B-cell compartment nor is necessary linked to the c-Myc 
induced activation of the cluster 89. 
It is well established that miRNA are able to regulate several targets at the same time, affecting different 
pathways or multiple nodes on the same pathway 1. Moreover clusterization of miRNAs likely evolved to 
coordinate miRNA tuning of the cell transcriptome thus eliciting a more complex response. In this scenario the 
stronger oncogenic potential of the full-length miR17~92 cluster, compared to the miR-19 family alone, can be 
partially explained by assuming that the other members of the cluster are actively cooperating with miR-19 by 
enhancing repression of their common targets (e.g. PTEN) or downregulating additional targets. Moreover, 
since only 46 out of 95 genes found upregulated following miR-19 deletion were functionally validated, 
additional relevant targets might come out from an extended analysis of the gene expression analysis data. 
A systematic mutational analysis demonstrated that the oncogenic potential of miR-19b is entirely dependent on 
the seed sequence. A possible explanation is that disrupting the seed sequence completely or partially affects 
miR-19b ability to interact with its targets. In fact, even a partial loss of affinity towards a target’s binding site 
could lower the repressive effect and abrogate miR-19b anti-apoptotic activity. Despite evolutionary conserved, 
the non-seed sequence seemed to have a minor role in the target recognition process. Perhaps the non-seed 
primary function is to drive the processing of the miRNA precursor or the correct assembly of the mature 
miRNA into the RISC complex. Analysis of the gene expression profile, for each mutant we have generated, 
will allow us to determine whether loss of PTEN repression can fully explain miR-19b loss of activity and 
possibly identify additional important miR-19b targets. Moreover, in order to confirm that the observed 
difference in oncogenic effects reflects a true functional difference rather than a difference in the expression 
levels, we need to verify whether the mutants are correctly processed and expressed at levels comparable to that 
of the wild type miR-19b. Finally we will also test, in vivo, the oncogenicity of the mutants. 
In conclusion, the findings described in this manuscript provide a solid explanation for the functional 
cooperation of miR-17~92 and c-Myc. They further demonstrates that miR-17~92 is required for tumorigenesis 
and its oncogenic potential is completely dependent on miR-19b.  To our knowledge, we are among the first to 
show that mutations in the mature sequence of an oncogenic miRNA have an impact on the growth of cancer 
cells. Finally, our results have important implications for the development of novel anti-cancer therapies based 
on miRNA inhibitor as targeting miR-19b might be an effective treatment against apoptosis-resistant tumors.  
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PART II 
In this study we shed light on the molecular mechanisms and the factors involved in miR-17~92 regulation of 
angiogenesis. In our preliminary work, we observed a miR-20b dependent regulation of the pro-angiogenic 
factor VEGF in an in vitro model of breast cancer. Deregulation of the VEGF signaling pathway in solid tumors 
has a strong impact on tumor progression as it stimulates the growth of blood vessels to provide nutrients and 
oxygen to the tumor cells 48. In accordance with our findings, members of the miR-17 family have been reported 
to target VEGF in tumors 50, 51. VEGF is a master regulator of cardiovascular development and deregulation of 
developmental pathways is commonly associated with cancer. When we looked at mouse cardiovascular 
development, we indeed found that embryos lacking miR-17~92 alone or together with its paralog miR-
106a~363, have a defective heart and a profoundly altered vascular pattern. VEGF was found to be upregulated, 
but it was not directly regulated by miR-17~92. VEGF increase in embryos could be indirectly caused by the 
absence of miR-17~92. Indeed, cardiac defects might be responsible for an insufficient blood circulation that 
causes tissues to become hypoxic and ultimately leads to the activation of a VEGF-mediated angiogenic 
response. Another possible explanation is that the interaction between miR-17~92 and VEGF is restricted to a 
particular cell-type (e.g. endothelial cells) or is context-dependent.  
Our data support the idea that miR-17~92 negatively regulates angiogenesis. Accordingly, a recent report 
showed that individual miR-17~92 members have anti-angiogenic properties 70. However, further analyses are 
required in order to identify the critical targets affecting vascular development. In recent years, some reports 
have attributed to this cluster of miRNAs a proangiogenic role in tumors 69. It is possible that in a tumorigenic 
context miR-17~92 function is altered, as a consequence of multiple deregulated or constitutively activated 
oncogenic pathways.  
In the last few years researchers have focused their attention on the development of anti-angiogenic drugs for 
the treatment of solid tumors. Understanding the physiologic role of miR-17~92 in controlling angiogenesis will 
be of great help in developing new anti-cancer therapies based on miRNA mimics or inhibitors. 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The miR-17~92 cluster is frequently amplified or over-
expressed in human cancers and has emerged as the
prototypical oncogenic polycistron microRNA (miRNA).
miR-17~92 is a direct transcriptional target of c-Myc, and
experiments in a mouse model of B-cell lymphomas
have shown cooperation between these two oncogenes.
However, both the molecular mechanism underlying
this cooperation and the individual miRNAs that are
responsible for it are unknown. By using a conditional
knockout allele of miR-17~92, we show here that sus-
tained expression of endogenous miR-17~92 is required
to suppress apoptosis in Myc-driven B-cell lymphomas.
Furthermore, we show that among the six miRNAs that
are encoded by miR-17~92, miR-19a and miR-19b are
absolutely required and largely sufficient to recapitulate
the oncogenic properties of the entire cluster. Finally, by
combining computational target prediction, gene ex-
pression profiling, and an in vitro screening strategy, we
identify a subset of miR-19 targets that mediate its pro-
survival activity.
Supplemental material is available at http://www.genesdev.org.
Received October 11, 2009; revised version accepted
November 3, 2009.
The miR-17;92 cluster encodes six distinct microRNAs
(miRNAs) that are processed from a common primary
transcript (Fig. 1A; for review, see Mendell 2008). A
growing body of evidence points to an important role of
this cluster of miRNAs in the pathogenesis of human
cancers (for review, see Ventura and Jacks 2009). Over-
expression ofmiR-17;92 is observed in a large fraction of
human cancers, including carcinomas of the breast, lung,
and colon; medulloblastomas; neuroblastomas; and B-cell
lymphomas (Hayashita et al. 2005; He et al. 2005; Tagawa
and Seto 2005; Fontana et al. 2008; Uziel et al. 2009). In
addition, a substantial fraction of diffuse large B-cell
lymphomas harbors recurrent genomic amplification of
the miR-17;92 locus (Ota et al. 2004).
The evidence for a causal link between miR-17;92
overexpression and tumorigenesis is strengthened by the
observation that transgenic expression of this cluster in
mice leads to a lymphoproliferative disorder (Xiao et al.
2008), while its genetic ablation impairs normal B-cell
development (Ventura et al. 2008). In addition, ectopic
expression of miR-17;92 cooperates with the c-Myc
oncogene in a mouse model of B-cell lymphomas (He
et al. 2005). The functional interplay between miR-
17;92 and c-Myc is further underlined by the finding
that c-Myc itself is a potent and direct transcriptional
activator of miR-17;92 (O’Donnell et al. 2005), thus
suggesting that miR-17;92 may contribute to the onco-
genic properties of c-Myc.
The experiments presented in this study were designed
to examine the role of the endogenous miR-17;92 allele
in Myc-driven lymphomas, and to determine the relative
contribution of each of the six constituent miRNAs to
the overall oncogenic potential of the cluster.
Our results show that, in the context of Myc-driven
B-cell lymphomas, genetic ablation of the endogenous
miR-17;92 locus leads to a dramatic reduction of tumor
cell growth in vitro and suppresses tumorigenicity in
vivo, two effects that are largely the consequence of
increased cell death. We also demonstrate that, among
the six miRNAs encoded by the miR-17;92 cluster, the
members of the miR-19 family (miR-19a and miR-19b)
are essential to mediate the oncogenic activity of the
entire cluster, and that they do so at least in part by
modulating the expression of the tumor suppressor gene
Pten (phosphatase and tensin homologous).
Results and Discussion
Generation of miR-17;92flox/flox;Em-Myc mice
To investigate the role of miR-17;92 in Myc-induced
cancers, we employed the Em-Mycmouse model of B-cell
lymphomas (Adams et al. 1985). Em-Myc mice express a
c-Myc transgene under the control of the B-cell-specific
Em enhancer and develop B-cell lymphomaswithin 4–6mo
of age (Adams et al. 1985). Em-Myc mice were crossed to
mice carrying a conditionalmiR-17;92 knockout allele
(miR-17;92fl) (Fig. 1B; Ventura et al. 2008). To temporally
control the deletion of the floxedmiR-17;92 allele, these
mice were further crossed to mice carrying a 4-hydroxy-
tamoxifen (4-OHT)-inducible Cre-recombinase estrogen
receptor-T2 (Cre-ERT2) knock-in allele targeted to the
ubiquitously expressed ROSA26 locus (R26-Cre-ERT2
mice, hereafter referred to as Cre-ER) (Ventura et al.
2007).
As expected, Em-Myc; miR-17;92fl/fl; Cre-ER mice
developed B-cell lymphomas with similar latency and
phenotype as the parental Em-Myc strain (data not
shown). From these mice, we derived two independent
lymphoma lines (AV4174 and AV4182) that could be
[Keywords: microRNAs; Myc; miR-17;92; cancer; mouse]
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propagated easily in culture and readily formed tumors
when injected into immunocompromised mice. Both
lymphoma lines exhibited similar behavior in vitro and
in vivo. Unless otherwise specified, the experiments
discussed here were performed using the AV4182 cell
line.
To determine the efficiency of miR-17;92 deletion,
miR-17;92fl/fl lymphoma cells were treated with 250 nM
4-OHT. This treatment lead to the efficient deletion of
both endogenous miR-17;92 alleles (Fig. 1C), with con-
comitant loss of expression of the correspondingmiRNAs
(Fig. 1D).
We next examined the phenotypic consequences of
deleting miR-17;92 in B-lymphoma cells. Because sus-
tained Cre expression has been reported to negatively
affect the growth of Em-Myc lymphoma cells (Schmidt-
Supprian and Rajewsky 2007), 4-OHT was administered
for 4 d, after which the lymphoma cells were allowed to
recover for a minimum of 4 d before being examined. As
shown in Figure 1E, deletion of miR-17;92 dramatically
reduced the proliferation of Em-Myc lymphoma cells.
Importantly, this phenotype was fully rescued by reintro-
duction of the entire miR-17;92 cluster (Fig. 1E).
The different growth kinetics between the miR-
17;92fl/fl and miR-17;92D/D lymphoma cells could be
due to the latter displaying reduced proliferation, in-
creased spontaneous cell death, or a combination of both.
While cell cycle distribution and BrdU incorporation
were similar between miR-17;92fl/fl and miR-17;92D/D
cells (Supplemental Fig. 1A), the fraction of cells un-
dergoing apoptosis, as determined by detecting caspase
activation, was approximately fourfold higher in the
absence of miR-17;92 (Fig. 1F). Increased apoptosis was
confirmed by measuring the DNA fragmentation using
the TUNEL assay (Supplemental Fig. 1B). These results
demonstrate that expression of the endogenous miR-
17;92 locus is required for the optimal survival of Myc-
driven B-lymphoma cells. In addition, they are consistent
with the finding by He et al. (2005) that ectopic expres-
sion of miR-17;92 cooperates with c-Myc by reducing
spontaneous apoptosis.
miR-19a and miR-19b mediate the oncogenic
properties of miR-17;92
This observation provides a rationale and an opportunity
to genetically dissect the functions of this cluster and to
identify its relevant target mRNAs. The six miRNAs
encoded by miR-17;92 can be grouped into four ‘‘seed
families,’’ based on sequence identity at positions 2–7
(Fig. 1A): the miR-17 family (miR-17 and miR-20a), the
miR-18 family (miR-18a), themiR-19 family (miR-19a and
miR-19b-1), and the miR-92 family (miR-92-1). miRNAs
belonging to the same seed family are predicted to target
highly overlapping sets of mRNAs, and thus are expected
to exert similar biological functions (Bartel 2009). To
examine the role of each seed family in the context of
Em-Myc lymphomas, we generated a series ofmiR-17;92
mutant alleles, each lacking expression of the miRNA(s)
belonging to one of the four seed families (Supplemental
Fig. 2A). The wild-type and the mutant alleles of miR-
17;92 were cloned into MSCV-Puro-IRES-GFP (PIG),
a retroviral vector encoding the green fluorescent protein
(GFP) and the Puromycin resistance gene, and the result-
ing constructs were transduced into miR-17;92D/D lym-
phoma cells. First, we verified that these constructs
correctly expressed the desired miRNAs (Supplemental
Fig. 2B). This was an essential control because deletion of
even a single miRNA from themiR-17;92 cluster could,
in principle, negatively affect the processing and expres-
sion of the remaining ones, thus compromising our
experimental approach.
To determine the ability of each construct to rescue the
phenotype caused bymiR-17;92 deletion, we titrated the
viral preparations to achieve an infection efficiency of
5%–30%, as judged by GFP expression. We reasoned that,
if reintroduction ofmiR-17;92 or one of its derivatives is
sufficient to suppress the increased cell death observed in
miR-17;92D/D cells, it will provide the infected cells with
a growth advantage that will in turn be reflected by an
increase in the fraction of GFP-positive cells over time
(see schematic in Fig. 2A). As predicted, reintroduction of
the full-length miR-17;92 cluster resulted in a rapid
increase of GFP+ cells that quickly outcompeted the
uninfected cells (Fig. 2B). Interestingly, among the four
mutant constructs, only the one lacking the miR-19 seed
family (D19a, 19b) failed to provide a growth advantage
(Fig. 2B,C) and to suppress the increased apoptosis caused
by deletion of miR-17;92 (Fig. 2D), suggesting that this
seed family is necessary for the oncogenic properties of
the cluster. This was further confirmed by showing that
reintroduction ofmiR-19a andmiR-19b alone was largely
sufficient to rescue the growth defect caused by deletion
Figure 1. miR-17;92 suppresses cell death in Em-Myc lymphomas.
(A) Schematic representation of the miR-17;92 cluster. Each
miRNA is represented by a colored box and is color-coded based
on the seed family to which it belongs. The sequence of each mature
miRNA is also shown. (B) Schematic of the conditional miR-17;92
knockout allele. Arrows represent the primers used to detect the
floxed and the deleted (D) alleles. (C) PCR on genomic DNA ex-
tracted from Em-Myc;miR-17;92fl/fl;Cre-ER lymphoma cells mock-
treated or after 4 d of 4-OHT treatment. (D) Quantitative RT–PCR
analysis of the expression of miR-17;92 in lymphoma cells before
(gray bars) and after (white bars) 4-OHT treatment. Each component
of miR-17;92 was detected independently, and the results were
normalized relative to the expression observed in mock-treated
cells. Each experiment was performed in quadruplicate. Error
bar, standard deviation (SD). (E) Growth curves of miR-17;92fl/fl
cells (black line), miR-17;92D/D cells (red line), and miR-17;92D/D
cells infected with a retrovirus expressing the entire miR-17;92
cluster (blue line). Error bars, SD of three replicates. The plot is
representative of three independent experiments. (F) Caspase activity
in exponentially growing miR-17;92fl/fl and miR-17;92D/D lym-
phoma cells as detected by flow cytometry using FITC-conjugated
VAD-FMK. The percent of VAD-FMK+ cells is shown.
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of the entiremiR-17;92 cluster and to suppress apoptosis
(Fig. 2B,D, miR-19a,b construct).
Deletion of miR-19 affects tumorigenicity in vivo
To determine whether the miR-19 seed family is required
for the tumorigenicity of Em-Myc-driven B-cell lympho-
mas in vivo, we injected a cohort of nude mice withmiR-
17;92fl/fl and miR-17;92D/D lymphoma cells. While
miR-17;92fl/fl cells invariably lead to the formation of
lymphomas that lead to death within 2–3 wk, the miR-
17;92D/D cells produced lymphomas with a significantly
(P < 0.0001) longer latency (Fig. 2E). Tumorigenicity was
fully restored by ectopic expression of the full-length
miR-17;92 cluster (P < 0.0001), but not by expression of
the miR-17;92 mutant lacking miR-19a and miR-19b
(P = 0.9816) (Fig. 2E). Re-expression ofmiR-19a andmiR-
19b also largely rescued tumorigenicity, although it did
so somewhat less efficiently than the full-length miR-
17;92 (P = 0.0002 for the comparison between D/D and
D/D +miR-19a,b; P = 0.0013 for the comparison between
fl/fl and D/D + miR-19a,b).
Identification of miR-19 targets in B-cell lymphomas
Having demonstrated a critical role ofmiR-19a andmiR-
19b in Myc-driven B-cell lymphomas, we next sought
to identify their functionally relevant target mRNAs.
miRNA target prediction algorithms (TargetScan,
Miranda, and Pictar) (John et al. 2004; Krek et al. 2005;
Grimson et al. 2007; Betel et al. 2008) identify several
hundreds of potential targets of miR-19; however, only
a fraction of these mRNAs will likely be functionally
relevant in any particular cellular context. To identify the
genes whose expression is effectively modulated bymiR-
17;92 in B-cell lymphomas, we compared the
gene expression profile of the AV4182 cell line
before and after deletion of miR-17;92 (fl/fl vs.
D/D). We also included miR-17;92D/D lym-
phoma cells that had been transduced with
either PIG-miR-17;92wt or PIG-miR-19a/19b
(Fig. 3A). In choosing this approach, we were
supported by a number of recent reports show-
ing that mRNA destabilization contributes
to miRNA-mediated regulation of gene expres-
sion (Bagga et al. 2005; Lim et al. 2005; Baek
et al. 2008; Selbach et al. 2008), which can be
detected by conventional mRNA expression
arrays. As predicted, deletion of miR-17;92
led to the preferential up-regulation of genes
whose 39 untranslated regions (UTRs) contain
seed matches for the miRNAs encoded by this
cluster (P-value < 2.22e-16, KS test) (Fig. 3B;
Supplemental Fig. 3). Accordingly, ectopic ex-
pression of miR-17;92 in miR-17;92D/D cells
led to the preferential down-regulation of miR-
17;92 targets (P-value < 2.22e-16, KS test) (Fig.
3C; Supplemental Fig. 3). Finally, reintroduction
of a mutant version of the miR-17;92 cluster
expressing only miR-19a and miR-19b selec-
tively affected mRNAs carrying binding sites
for these two miRNAs (P-value = 6.35e-15), but
not genes with binding sites for the other
members of the miR-17;92 cluster.
By comparing the four gene expression pro-
files, we identified a total of 568 genes whose ex-
pression was up-regulated (log2 expression change >0.20)
by deletion of the endogenous miR-17;29 locus (fl/fl vs.
D/D comparison) and down-regulated by the reintroduc-
tion of the full-lengthmiR-17;92 cluster (miR-17;92 vs.
D/D) and of miR-19a and miR-19b only (miR-19a/b vs.
D/D; log2 expression change <!0.20) (Fig. 3D). Ninety-
five of them contained in their 39UTR one or more con-
served binding sites for miR-19, according to TargetScan
5.1 (Fig. 3E; Supplemental Table 1), and were analyzed
further. Guided by our findings that miR-19 suppresses
apoptosis in Em-Myc lymphoma cells, we inspected the
list of 95 genes and selected a subset of 46 of them for
functional validation (Fig. 4A; Supplemental Table 2). We
reasoned that, if miR-19 promotes survival by repressing
the expression of one or more of these genes, this effect
should be at least partially phenocopied by RNAi-medi-
ated knockdown of the relevant targets. To test this
hypothesis, for each of the 46 genes selected for validation
we designed three shRNAs. The shRNAs were cloned
into the MLP vector, a retroviral vector also expressing
GFP, and each construct was individually transduced into
miR-17;92D/D lymphoma cells. Analogous to the exper-
iments described in Figure 2A, the viral preparations were
titrated in order to achieve a transduction efficiency of
5%–30%, and the fraction of GFP+ cells was measured 2 d
after infection (day 0) and again 11 d later. The results of
this experiment are summarized in Figure 4B. For the
majority of shRNAs, the fraction of GFP+-positive cells
did not change over time or, for a small number of them,
was lower at day 11 compared with day 0, indicating that
expression of the shRNA did not provide any growth
advantage to the infected cells or was detrimental, re-
spectively (Fig. 4B; Supplemental Table 2). However, for
a subset of shRNAs, we observed a significant increase in
Figure 2. miR-19a andmiR-19b mediate the prosurvival and oncogenic functions
of miR-17;92 in Em-Myc B-cell lymphomas. (A) Schematic of the experimental
design. (B) Histogram overlays of miR-17;92D/D cells transduced with PIG
retroviruses expressing the indicated miR-17;92 derivatives. The cells were
assayed by flow cytometry to detect GFP expression at day 2 (blue plot) and day
8 (red plot) post-infection. A schematic of themiR-17;92 derivative used is shown
below each overlay. (C) Table summarizing the results of the experiments shown in
B. (D) Caspase activity in miR-17;92fl/fl and miR-17;92D/D cells transduced with
the indicated PIG constructs. Error bar, 1 SD deviation. (E) Survival analysis of
mice injected with miR-17;92fl/fl and miR-17;92D/D lymphoma cells transduced
with the indicated PIG constructs. N = 16 mice for each construct, over three
independent experiments.
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this case, survival was slightly longer comparedwithmice
injected with miR-17;92fl/fl cells (P = 0.0002), indicating
the existence of additional functionally relevant targets.
In summary, the results presented here provide a mech-
anistic explanation for the functional cooperation between
c-Myc and miR-17;92, identify the miR-19 seed family
as the primary oncogenic determinant of this cluster, and
pave the way for the development of novel anti-cancer
strategies based on the pharmacological inhibition of
miR-19 function.
Material and methods
Mouse husbandry
Animal studies and procedures were approved by the Memorial Sloan
Kettering Cancer Center Institutional Animal Care and Use Committee.
Mice were maintained in a mixed 129SvJae and C57/B6 background. The
Rosa26-Cre-ERT2 andmiR-17;92fl/fl mice have been described previously
(Ventura et al. 2007, 2008). The Em-Myc mice were generated and
described by Adams et al. (1985).
For the in vivo tumorigenicity studies, 4- to 8-wk-old athymic (nu/nu)
mice were injected intravenously with 105 lymphoma cells andmonitored
daily. Mice were euthanized when moribund. Kaplan-Meier curves were
plotted using PRISM software, and the log-rank Mantel-Cox test was used
to determine statistical significance.
Antibodies and immunohistochemistry
Antibodies and experimental conditions for Western blotting and immu-
nohistochemistry are described in the Supplemental Material.
Cell culture and retroviral transduction
The Em-Myc;miR-17;92fl/fl;Cre-ERT2 lymphoma lines were cultured on
a feeder of irradiated NIH-3T3 cells in a medium composed of 50%
DMEM and 50% IMDM, supplemented with 10% fetal bovine serum.
To induce deletion of the miR-17;92 cluster, cells were incubated for
4 d with 250 nM 4-OHT. During our initial set of experiments with
4-OHT-treated lymphoma cells, we noticed that, upon prolonged passages,
the few cells that had escaped full miR-17;92 deletion (miR-17;92fl/fl
and miR-17;92fl/D) invariably outcompeted the miR-17;92D/D cells,
eventually becoming the majority within a couple of weeks. To avoid
this limitation and allow the execution of long-term in vivo experiments,
4 d after 4-OHT treatment, subclones were isolated by plating 10 cells per
well into a 96-well plate using a MoFlo fluorescence-activated cell sorter.
After expansion, clones composed solely of fully recombined cells were
isolated and used for further manipulation.
Retroviruses were generated in Phoenix packaging cells. When re-
quired, transduced cells were selected by adding puromycin (2 mg/mL) to
the culture medium for 4 d.
Plasmids and shRNA library
A 1.2-kb fragment encompassing the entiremiR-17;92 cluster was PCR-
amplified from mouse genomic DNA and cloned into the MSCV-PIG
retroviral vector (a gift from Mike Hemann, Massachusetts Institute of
Technology). Deletion mutants were by site-directed PCR and verified by
sequencing. Primers and sequences are available on request.
The shRNA library was cloned in the MLP retroviral vector (a gift from
Michael Hemann, Massachusetts Institute of Technology). For each gene,
three shRNA directed against the coding sequence were designed using
the RNAi Central resource created by the laboratory of Greg Hannon
(http://katahdin.cshl.org:9331/siRNA/RNAi.cgi?type=shRNA). Each con-
struct was sequence-verified.
Apoptosis assays
Apoptosis was measured using the Caspase Detection Kit (Red-VAD-FMK
or FITC-VAD-FMK, Calbiochem) and confirmed using the TUNEL assay
(In Situ Cell Death Detection Kit, TMR red, Roche) following the
manufacturer’s instructions.
Gene expression analysis
Total RNA extracted from three technical replicates was hybridized to the
Affymetrix 430 A2.0 gene chip, following the manufacturer’s instruction.
Gene expression was normalized using the GCRMA Bioconductor pack-
age, and log expression values were computed using the limma package.
For genes with multiple probes, the probe with lowest adjusted P-value
Figure 5. Pten is a functionally relevantmiR-19 target in B-cell lymphomas. (A) Schematic representation of the Pten 39UTR with the location
of the predicted binding sites for members of the miR-17;92 cluster and sequence alignments between miR-19b and its two predicted binding
sites. (B) Pten Western blot on lysates of B-lymphoma cells transduced with the indicated PIG constructs. (Lanes 8,9) For comparison, lysates
from miR-17;92D/D cell expressing the two Pten shRNAs that scored positive in the in vitro screen were also assayed. (C) Pten
immunohistochemistry on lymphoma sections obtained from mice injected with miR-17;92fl/fl and miR-17;92D/D B-lymphoma cells trans-
duced with the indicated miR-17;92 derivatives (objective, 203). Brown staining indicates Pten signal. (D) Knockdown of Pten suppresses
apoptosis in miR-17;92D/D cells. Apoptosis was measured by detecting caspase activity in miR-17;92fl/fl and miR-17;92D/D cells transduced
with the indicated retroviruses. (E) Kaplan-Meier survival curve of mice injected with miR-17;92D/D lymphoma cells transduced with
retroviruses expressing shRNAs against Pten. N = 10 (five mice for shPTEN-1 and five mice for shPTEN-2). For comparison, the survival
curves of mice injected with miR-17;92fl/fl, miR-17;92D/D, and miR-17;92D/D + miR-19a,b from Figure 2C are included.
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was selected. Genes with a log expression change of <!0.2 in all three
comparisons and with an adjusted P-value < 0.05 in at least one
comparison were considered for subsequent overlap analysis.
miRNA target predictions
miRNA targets were predicted using miRanda (http://www.microrna.
org) and TargetScan (http://www.targetscan.org). For the cumulative
distribution function (CDF) plots, target sites were restricted to perfect
seed complementarity between positions 2 and 7 of the miRNA. Empir-
ical cumulative distributions were computed using R ecdf function for the
set of predicted gene of the transduced miRNAs and for the genes with no
target sites (background). P-values were computed using the KS two-
sample test.
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ExpressionQ1 of Angiogenic
Regulators, VEGF and Leptin, Is
Regulated by the EGF/PI3K/STAT3
Pathway in Colorectal
Cancer Cells
SANDRA Q3CASCIO,1 RITA FERLA,1,2 ALECO D’ANDREA,1 ALDO GERBINO,3
BAZAN VIVIANA,1 EVA SURMACZ,2 AND ANTONIO RUSSO1*
1Department of Surgical and Oncological Sciences, Section of Medical Oncology, Universita` di Palermo, Palermo, Italy
2Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, Pennsylvania
3Histological and Embriological Section, Department of Experimental Medicine, Institute of Pathology,
Universita` di Palermo, Palermo, Italy
Both leptin and vascular endothelial growth factor (VEGF) are growth and angiogenic cytokines that are upregulated in different types of
cancer and have been implicated in neoplastic progression. Here we investigated the molecular mechanism by which leptin and VEGF
expression are regulated in colon cancer by epidermal growth factor (EGF). In colon cancer cell line HT-29, EGF induced the binding of
signal transducer and activator transcription 3 (STAT3) to STAT3 consensus motifs within the VEGF and leptin promoters and stimulated
leptin and VEGF mRNA and protein synthesis. All these EGF effects were significantly blocked when HT-29 cells were treated with an
inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, LY294002, or with small interfering RNA (siRNA) targeting STAT3. Thus, our
study identified the EGF/PI3K/STAT3 signaling as an essential pathway regulating VEGF and leptin expression in EGF-responsive colon
cancer cells. This suggests that STAT3 pathways might constitute attractive pharmaceutical targets in colon cancer patients where anti-
EGF receptor drugs are ineffective.
J. Cell. Physiol. 9999: 1–6, 2009. ! 2009 Wiley-Liss, Inc.
Neoangiogenesis is a critical step for tumor growth and
metastatic spread (Folkman, 1971). New blood vessels
formation depends on the balance between positive and
negative regulators and is induced when factors that promote
angiogenesis are upregulated or those that inhibit angiogenesis
are down-regulated (Ferrara and Kerbel, 2005).
Vascular endothelial growth factor (VEGF) plays amajor role
in tumor angiogenesis and its expression is inversely correlated
with patient survival in many human cancers, including colon
carcinomas (Logan-Collins et al., 2008; Zafirellis et al., 2008).
VEGF expression is regulated by various signaling pathways
induced by external stimuli (e.g., hypoxia, hormones, cytokines)
and may depend on the cellular context (e.g., the presence of
activated oncogenes) (Xu et al., 2005). Epidermal growth factor
(EGF) receptor (EGFR) signaling pathway is commonly
activated in colorectal cancer and has been investigated as a
target for cancer therapy (Mendelsohn and Baselga, 2000).
After ligand (EGF, transforming growth factor) binding to
EGFR, a cascade of downstream signaling is activated, including
activation of the Ras-MAP kinase and phosphoinositide 3-kinase
(PI3K)/Akt pathways (Mendelsohn and Baselga, 2000).
Moreover, in several cell lines, EGF as well as abnormal
activation of EGFR signaling pathways induces VEGF expression
(Maity et al., 2000; Zhong et al., 2000). Conversely, EGFR
inhibition can decrease VEGF expression, and consequently
angiogenesis, in many tumor types (Ciardiello and Tortora,
2001; Pore et al., 2006).
A less well-known factorwith a strong neoangiogenic activity
is leptin (Cao et al., 2001; Anagnostoulis et al., 2008). Leptin is a
pleiotropic hormone whose major role is to regulate food
intake and energy balance via hypothalamic effects. Leptin also
affects many peripheral organs, behaving as a mitogen, survival
factor, metabolic regulator, or angiogenic factor (Wauters
et al., 2000; Cao et al., 2001; Misztal-Dethloff et al., 2004;
Gonzalez et al., 2006). Furthermore, there is evidence that
leptin promotes neoplastic processes in different cell types
(Garofalo et al., 2006; Housa et al., 2006). In colorectal cancer,
leptin can promote proliferation and invasiveness, and inhibit
apoptosis (Attoub et al., 2000; Aparicio et al., 2004; Amemori
et al., 2007; Jaffe and Schwartz, 2008). In addition, human
colorectal cancers have been shown to overexpress leptin as
well the leptin receptor (ObR) (Koda et al., 2007).
The VEGF and leptin gene promoters contain several
regulatory motif as ERE, CRE, SP-1, AP-2, HRE, and SRE
(STAT3-responsive element) (Finkenzeller et al., 1997; Mason
et al., 1998; Brenneisen et al., 2003). STAT3 is a transcription
factor activated through phosphorylation on a conserved
tyrosine residue (Tyr705), leading to STAT3 dimerization,
nuclear translocation and DNA binding to specific consensus
sequence TT(N4/5)AA (Seidel et al., 1995; Frank, 2007). STAT3
has been identified as a major regulator of VEGF expression in
glioblastoma and prostate cancer (Niu et al., 2002; Wei et al.,
2003). VEGF induction by various oncogenic growth stimuli,
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including IL-6, c-src, Her2/Neu can be abrogated by
interruption of STAT3 signaling with dominant-negative STAT3
protein or STAT3 antisense nucleotide (Wei et al., 2003; Xu
et al., 2005).
Recently data demonstrated that STAT3 is involved in
colorectal cancer cells growth, survival, invasion, and migration
(Klampfer, 2008), through upregulation of various genes,
including VEGF (Xiong et al., 2008). However, the role of STAT3
in VEGF or leptin expression in colorectal cancer has never
been assessed.
Because the growth of colorectal cancer cells can be
regulated by the EGF/STAT3 pathway (Alvarez et al., 2006;
Vigneron et al., 2008), we tested if this pathway can be involved
in the activation of two angiogenic factors, VEGF and leptin.
Here we demonstrated that in colorectal cancer cell line
HT-29, EGF-induced leptin andVEGF expression ismediated by
the recruitment of STAT3 to SRE motif in both VEGF and leptin
gene promoters. EGF effects on VEGF and leptin expression
were significantly blocked with small interfering RNA (siRNA)
targeting STAT3.
Materials and Methods
Cell culture and treatments
HT-29 cells were grown in GIBCOTM Leibovitz’s L-15 Medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS), 100U/mL penicillin, and 50mg/mL streptomycin.
A total of 70% confluent cells were synchronized in serum-free
medium (SFM) for 24 h and then stimulated with 10 ng/ml EGF
(R&D Systems, Minneapolis, MN) for 24 h, with or without a 2 h
pre-treatment of PI3K inhibitor LY294002 (Calbiochem, San
Diego, CA) at 50mM.
Quantitative real-time-PCR (qRT-PCR)
HT-29 cells were treated, as described above, or left untreated.
Total cellular RNAwas isolated using the RNeasyMini Kit (Qiagen,
Inc., Valencia, CA). A total of 5mg of RNAwas reverse transcribed
using the High-Capacity cDNA Archive (Applied Biosystems,
Foster City, CA) according to the manufacturer’s protocol. Five
microliters of the RT products were used to amplify leptin and
VEGF sequences using respectively the Hs00174877_m1 Lep and
the Hs00900054_m1 VEGF TaqMan Kit (Applied Biosystems),
following vendor’s instructions. To normalize qRT-PCR reactions,
parallel reactions were run on each sample for cyclophilin A.
Changes in the target mRNA content relative to cyclophilin A
mRNA were determined using a comparative CT method to
calculate changes in CT, and ultimately fold and percent change. An
average CT value for each RNA was obtained for replicate
reactions.
Leptin and VEGF detection by ELISA
A total of 3.6! 107 HT-29 cells (or 1.8! 107 for STAT3 siRNA)
were treated, as above described. Secreted VEGF and leptin were
measured in cell culture media using HumanQuantikine ELISA Kits
(R&D Systems) with the lowest detection limit of 5 pg/ml for VEGF
and 7.8 pg/ml for leptin, intra-assay precision of <8.8% (VEGF)
and <4.9% (leptin), and inter-assay precision <9.2% (VEGF) and
<8.2% (leptin). All points were done in triplicate and the
experiments were repeated three times. All leptin and VEGF
concentrations were within the range of curve standard. Linear
regression analysis was performed to create the curve standard.
Western blotting (WB)
Cytoplasmic and nuclear protein extraction was performed using
NE-PER Extraction Reagents (Pierce Biotechnology, Inc.,
Rockford, IL). The expression of STAT3 was analyzed in 120mg of
cytoplasmic or nuclear cell lysates. The following antibodies were
used for WB: anti-STAT3 (C-20 X), anti-C23 (MS-3), and
anti-GAPDH (8C2). All above antibodywere purchased from Santa
Cruz (Santa Cruz Biotechnology, Santa Cruz, CA). Nuclearmarker
nucleolin and cytoplasmic marker GAPDH were used as loading
controls.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the Chromatin Immunoprecipitation
Assay kit (Upstate, Temecula, CA), according to manufacturer’s
instructions. Soluble chromatin was immunoprecipitated with
STAT3 (C-20) pAb (Santa Cruz Biotechnology). The presence of
leptin and VEGF promoter domains containing STAT3 motifs in
immunoprecipitated DNA was identified by PCR using the
following primers: for leptin (region from "1892 to "1403)
forward 50-TTG TGG TCA GAC CAG TTT TCT-30, reverse
50-GTT TGG TAA TGC CCA AAA GCT-30, for VEGF (region
"1041 from to "750) forward 50-CAG GAA CAA GGG CCT
CTG TCT-30, reverse 50-TGT CCC TCT GAC AAT GTG CCA
TC-30. The PCR conditions for leptin region were: 1min at 948C,
1min at 608C, 1min at 728C; for VEGF region: 1min 948C, 1min at
648C, 1min at 728C. The amplification of these regions was
analyzed after PCR 35 cycles.
Knockdown of STAT3 using small interfering RNA (siRNA)
STAT3 knockdowns were achieved using siRNAs (Dharmacon,
Inc., Lafayette, CO), according to manufacturer’s instructions.
Twenty-four hours following transfection, the cells were placed in
SFM for 24 h, then stimulated with EGF 10 ng/ml for 24 h or left
untreated. Non-specific siRNA (Dharmacon, Inc.) was used as a
negative control.
Results
EGF upregulates VEGF and leptin expression
Since it is known that EGF regulates tumor-associated
angiogenesis, we assessed EGF effects on the expression of
VEGF and leptin. First, wemeasured the effects of EGF onVEGF
and leptinmRNA levels. The treatment of HT-29 cells with EGF
for 24 h induced VEGF mRNA production by 1.4-fold (Fig. 1a).
Similarly, EGF stimulated leptinmRNAexpression by 2.7-fold at
24 h relative to untreated cells (Fig. 1b). In parallel, EGF
increased the levels of secreted VEGF and leptin by 2.6- and
1.7-fold, respectively (Fig. 1c,d). These results suggested that
EGF upregulates VEGF and leptin at mRNA and protein levels.
EGF-induced STAT3 recruitment to VEGF
and leptin promoters
Analysis of the VEGF promoter revealed a putative binding site
for STAT3 at the "848 position (Niu et al., 2002). We also
identified two binding sites for STAT3 within the leptin
promoter at"1715 and at"1500 positions. Consequently, we
investigated whether STAT3 could mediate EGF effects on
VEGF and leptin expression in HT-29 colon cancer cell line.
We first examined the abundance of nuclear STAT3 in cells
treated with EGF (Fig. 2a). In untreated cells, STAT3 was
expressed in the nucleus at relatively low levels, while following
EGF stimulation, nuclear accumulation of STAT3 was
significantly increased (2.5-fold, relative to untreated cells); at
the same time, the cytoplasmic STAT3 levels remained
unchanged. Next, we assessed STAT3 binding to specific motifs
in the VEGF and leptin promoters (Fig. 2b). Our results
suggested that EGF increased STAT3 recruitment to both VEGF
and leptin promoters by threefold.
Silencing of STAT3 expression reduces VEGF and
leptin induction by EGF
To verify STAT3 involvement in EGF-induced VEGF and leptin
mRNA production, we silenced STAT3 expression using RNA
interference. The specific STAT3 siRNA down-regulated basal
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Fig. 1. Leptin andVEGFmRNAandproteinexpression increases in response toEGFstimulation. a,b:TheabundanceofVEGFand leptinmRNA
were studied with qRT-PCR. HT-29 cells were synchronized in SFM for 24h and then treated with 10ng/ml EGF for 24 h or left untreated.
TonormalizeqRT-PCRreactions, parallel reactionswere runoneach sample for cyclophilinA.Thegraphs represent increase ofVEGFand leptin
mRNA relative to SFMWSD. M, P<0.05, control versus EGF. c,d: The abundance of VEGF and leptin proteins were determined by ELISA assay.
A total of 3.6T 107 HT-29 cells were treated as previously described.
Fig. 2. EGF increases nuclear STAT-3 level and induces loading on the VEGF and leptin promoters. a: HT-29 cells at 70% confluence were
synchronizedinserum-freemedium(SFM)for24 handthenstimulatedwith10 ng/mlEGFfor24 h.TheexpressionofSTAT3wasassessedbyWBof
100mgcytoplasmicand120mgnuclearproteinsusingspecificAbs,asdescribed inMaterialandMethodsSection.GraphsrepresentrelativeSTAT3
expression level normalized to nuclearmarker nucleolin and cytoplasmicmarkerGAPDH;Columns, mean; bars, SD; M, P<0.05 basal versus EGF.
b: The binding of STAT-3 on both leptin and VEGF promoters was assessed by ChIP as described in Material and Methods Section. The graphs
represent the abundance of STAT3 on VEGF and leptin promoters under different conditionsWSD; M, P<0.05 basal versus EGF-treated Columns,
mean; bars, SD.
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STAT3 protein levels by 90%, whereas unrelated siRNA had no
effects on this protein (Fig. 3a). STAT3 knockdown reduced by
16% and 48% EGF-induced VEGF and leptin mRNA levels
respectively as well as down-regulated basal levels of both
factors (Fig. 3b). Similarly, STAT3 siRNA reduced EGF-induced
secreted VEGF and leptin proteins by 35% and 25%,
respectively (Fig. 3c).
PI3K pathway is involved in EGF-dependent VEGF
and leptin expression
The PI3K pathway can regulate VEGF and leptin expression in
different cancer cell lines (Maity et al., 2000; Pore et al., 2003;
Saxena et al., 2007). Using LY294002 inhibitor, we investigated
whether this pathway is required for VEGF and leptin
transcriptional regulation in HT-29 cells (Fig. 4c). Inhibition of
the PI-3K pathway down-regulated EGF-dependent VEGF and
leptin mRNA by 20%, LY294002 also blocked basal level of
VEGF mRNA by 70%, whereas basal level of leptin was not
affected (Fig. 4c).
Next, we studied whether inhibition of PI3K can affect
EGF-induced recruitment of STAT3 to the VEGF and leptin
promoters. First, we found that nuclear accumulation of STAT3
was inhibited by 30% under LY294002 treatment (Fig. 4a). This
was followed by reduced EGF-dependent binding of STAT3 to
the VEGF and leptin promoters by 30% and 50%, respectively
(Fig. 4b).
Discussion
Angiogenesis is an essential process for the growth of primary
tumor and metastasis formation and VEGF is a recognized
critical factor involved in this process (Folkman, 1971). Tumor
cells may produce VEGF in response to stimuli, such as
cytokines and growth factors, such as EGF, or under hypoxic
conditions. Angiogenesis might also be induced by leptin,
directly, or indirectly through upregulation of VEGF (Cao et al.,
2001; Misztal-Dethloff et al., 2004; Suganami et al., 2004;
Anagnostoulis et al., 2008). Here we studied the molecular
mechanism by which EGF can promote angiogenesis in
colorectal cancer cells, focusing on EGF-dependent activation
of pro-angiogenic factors, VEGF and leptin.
We found that in HT-29 colon cancer cell lines, VEGF and
leptin levels were upregulated under EGF stimulation. Using
qRT-PCR and ELISA assays, we documented increased
Fig. 3. Knockdownof STAT3 reducesVEGFand leptin expression. a: Theexpression of STAT3wasdeterminedbyWB. Stat3knockdownswere
achievedusingsiRNAsasdescribed inMaterialandMethodsSection.After24 hfromtransfection,cellswereplaced inSFMfor24hthenstimulated
with EGF 10ng/ml for 24 h or left untreated. Non-specific siRNA was used as a negative control. Columns, mean; bars, SD; M, P<0.05 SFM
versus treated cells. b: The expression of VEGF and leptinmRNA in STAT3 siRNA transfectants treated for 24 h with EGF or left untreated was
studiedbyqRT-PCR.c:Atotalof1.8T 107cellsweretreatedasdescribedabove.TheabundanceofsecretedleptinandVEGF(pg/ml) inconditioned
medium was determined by ELISA. Columns, mean; bars, SD; M or MM, P<0.05 basal versus siSTAT3 trasfectant or EGF versus EGFR siSTAT3
trasfectant.
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expression of both factors at mRNA and protein level. These
data are in agreement with the observation that in glioblastoma
and prostate cancer cells, EGF can induce VEGF expression
(Maity et al., 2000; Zhong et al., 2000). However, direct
mechanistic link between EGF and VEGF in colon cancer cells
has not been described until now.Moreover, to our knowledge,
our data provide the first mechanistic evidence on the role of
EGF in the control of leptin expression in cancer cells.
It is known that VEGF promoter contains binding sites for
STAT3. A recent study in mouse cerebral endothelial cells
identified STAT3-mediated VEGF expression induced by
ectopic decorin, a ligand for EGFR (Santra et al., 2008). The
leptin promoter also contains two potential sites for STAT3
localized at !1715 and !1500 in the promoter. While it is
known that STAT3 activation mediates many of the biological
effects of leptin (Catalano et al., 2008), there are not evidences
regarding STAT3 involvement in leptin gene transcription. Our
study demonstrated for the first time that EGF-induced leptin
and VEGF expression in colon cancer is mediated by and
requires STAT3. Specifically, our results suggested that STAT3
binds both VEGF and leptin promoters under EGF stimulation
in colon cancer cells and STAT3 down-regulation by
RNA-interference significantly suppressed both VEGF and
leptin expression.
Our previous study in cancer cells suggested that PI3K is
involved in leptin expression (Bartella et al., 2008). PI3K
involvement in leptin expression was also confirmed in other
cell models (Cong et al., 2007; Tong et al., 2008). The PI3K/
mTOR pathway has also been shown to play an important role
in VEGF regulation (Zhong et al., 2000; Laughner et al., 2001;
Kang et al., 2008). In agreement with these observations, we
found that PI-3K is required for leptin and VEGF expression
under EGF treatment, especially for STAT3 recruitment to
both VEGF and leptin promoters, as demonstrated by ChIP
assay.
In summary, we demonstrated that in colorectal cancer cells,
EGF can upregulate the expression of two pro-angiogenic
factors, VEGF and leptin via the PI3K signaling pathway. We
report that the mechanism of this EGF-activity occurs at
transcriptional level and it is mediated by the recruitment of
STAT3 on VEGF and leptin promoters. The fact that EGF can
stimulate leptin expression in colon cancer suggest that leptin
and its receptor can become novel pharmaceutical targets in
colorectal cancer. In addition, STAT3, which appears to play a
major role in regulation of genes involved in angiogenesis might
serve as alternative target in colon cancer patients in which
anti-EGFR therapies are not effective.
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